



(86) Date de dépôt PCT/PCT Filing Date: 2006/08/18
 (87) Date publication PCT/PCT Publication Date: 2007/02/22
 (45) Date de délivrance/Issue Date: 2012/04/24
 (85) Entrée phase nationale/National Entry: 2008/02/15
 (86) N° demande PCT/PCT Application No.: JP 2006/316249
 (87) N° publication PCT/PCT Publication No.: 2007/021003
 (30) Priorité/Priority: 2005/08/18 (JP2005-237759)

(51) Cl.Int./Int.Cl. *C12Q 1/68* (2006.01),
C07H 21/00 (2006.01), *C07K 16/18* (2006.01),
C12N 15/12 (2006.01), *C12Q 1/02* (2006.01),
G01N 33/53 (2006.01)
 (72) Inventeurs/Inventors:
 ONO, YUICHI, JP;
 NAKAGAWA, YASUKO, JP;
 NAKATANI, TOMOYA, JP;
 SAKAMOTO, YOSHIMASA, JP
 (73) Propriétaire/Owner:
 EISAI R & D MANAGEMENT CO., LTD., JP
 (74) Agent: SMART & BIGGAR

(54) Titre : NATO3, MARQUEUR DE CELLULE PROGENITRICE DE CROISSANCE DE NEURONE PRODUCTEUR DE DOPAMINE
 (54) Title: DOPAMINERGIC NEURON PROLIFERATIVE PROGENITOR CELL MARKER NATO3

(57) **Abrégé/Abstract:**

The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of a Nato3 gene, or a complementary sequence thereto, and an antibody against a Nato3 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell.

ABSTRACT

The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a
5 polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of a Nato3 gene, or a complementary
10 sequence thereto, and an antibody against a Nato3 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell.

SPECIFICATION

DOPAMINERGIC NEURON PROLIFERATIVE PROGENITOR CELL
MARKER Nato3

5

Technical Field

[0001]

The present invention relates to a Nato3 gene, which is a dopaminergic neuron proliferative progenitor cell marker. More particularly, the present invention relates to a means for detecting a dopaminergic neuron proliferative progenitor cell, a method for detecting the cell, and a kit for detecting the cell.

10

Background Art

15 [0002]

The dopamine system is a very important system involved in movement control, hormone secretion control, affectivity control, and so forth, which are important in the mammalian brain. Therefore, abnormalities in dopaminergic neurotransmission cause various disorders of the neural system. For example, the Parkinson's disease is a neurodegenerative disease of the extrapyramidal system which is caused by specific degeneration of dopaminergic neurons in the midbrain substantia nigra (HARRISON'S PRINCIPLES OF INTERNAL MEDICINE Vol. 2 23rd ed., Isselbacher et al. edited by McGraw-Hill Inc., NY (1994) pp. 2275-7).

20

25

[0003]

As a method for treating the Parkinson's disease, a method of orally administering L-DOPA (3,4-dihydroxy-phenylalanine) has been mainly adopted for compensating the decrease in the amount of the produced dopamine, but it is known that the duration of the effect is not good.

30

[0004]

Accordingly, as a method for compensating the loss of dopaminergic neurons, recently, there has been attempted a therapeutic method of transplanting a midbrain ventral region of a

35

6-9 week aborted fetus containing dopaminergic neuron precursors (US Patent No. 5690927; Spencer et al. (1992) N. Engl. J. Med. 327:1541-8; Freed et al. (1992) N. Engl. J. Med. 327:1549-55; Widner et al. (1992) N. Engl. J. Med. 327:1556-63; Kordower et al. (1995) N. Engl. J. Med. 332:1118-24; Defer et al.(1996) Brain 119:41-50; and Lopez-Lozano et al. (1997) Transp. Proc. 29:977-80). However, at the present time, in addition to cell supply and ethical issues (Rosenstain (1995) Exp. Neurol.33:106; Turner et al. (1993) Neurosurg. 33:1031-7), various other problems have been indicated, for example, risk of infectious contamination, immunologic transplant rejection (Lopez-Lozano et al. (1997) Transp. Proc. 29:977-80 and Widner and Brudin(1988) Brain Res. Rev. 13:287-324), low survival rate due to the fetus tissue's mainly dependence on lipid metabolism rather than glycolysis (Rosenstein (1995) Exp. Neurol. 33:106), and so forth.

[0005]

As a method for solving the problem of the ethical issues or supply shortage, for example, a method by using a cortex, a striation, and midbrain cells, derived from a pig, and so forth have been proposed (for example, Japanese Patent Laid-Open Publication No. 10-508487, No. 10-508488, and No. 10-509034). However, in this method, a complex procedure for modifying an antigen on the cell surface (MHC class I antigen) is required to suppress rejection. As a method for solving the transplant rejection, for example, a method involving local immunosuppression by simultaneously transplanting Sertoli cells has been proposed (Japanese Patent Laid-Open Publication No. 11-509170 and No. 11-501818; and Selawly and Cameron (1993) Cell Transplant 2:123-9). It is possible that transplant cells are obtained from a relative whose MHC matches, bone marrow of another person, a bone marrow bank, a cord blood bank, and so forth. However, if patient's own cells can be used, the problems of rejection can be solved without extra procedures and trouble.

[0006]

Accordingly, it has been expected that, instead of cells derived from an aborted fetus, a differentiation system of

dopaminergic neurons *in vitro* from non-neural cells such as embryo-stem (ES) cell and bone marrow stromal cells are utilized as a transplant material. Actually, there is a report that a functional dopaminergic neuron is formed by ES cell transplantation
5 into lesion striation of a rat Parkinson's disease model (Kim et al. (2002) Nature 418:50-56). It is thought that in the future, importance of regenerative medicine from ES cells or the patient's own neural stem cells will increase.

[0007]

10 On the other hand, in the treatment of damage of neural tissue, restructuring of brain function is required, and for forming appropriate linkage with surrounding cells (network formation), not mature cells but progenitor cells that can differentiate into neurons
15 *in vivo* are required to be transplanted. However, in the transplantation of neuron progenitor cells, in addition to the above-described problem regarding supply, there is a problem that the progenitor cells can differentiate into a nonuniform cell population. For example, in the treatment of the Parkinson's disease, it is necessary that dopaminergic neurons are selectively
20 transplanted among catecholamine-containing neurons. Before now, as transplant cells for use in the treatment of the Parkinson's disease, there has been proposed a striate body (Lindvall et al. (1989) Arch. Neurol. 46:615-31 and Widner et al. (1992) N. Engl. J. Med. 327:1556-63), an immortalized cell line derived from human
25 embryonic nerve (Japanese Patent Laid-Open Publication No. 8-509215, No. 11-506930, and No. 2002-522070), a post-mitotic human neuron of NT2Z cells (Japanese Patent Laid-Open Publication No. 9-5050554), a neuron primordial cell (Japanese Patent Laid-Open Publication No. 11-509729), a cell transfected
30 with an exogenous gene so as to produce catecholamine such as dopamine, a bone marrow stromal cell (Japanese Patent Laid-Open Publication No. 2002-504503 and No. 2002-513545), an ES cell in which a gene is modified (Kim et al. (2002) Nature 418:50-56), and so forth. However, none of these contain only dopaminergic
35 neurons or cells to differentiate into dopaminergic neurons.

[0008]

As a method for selectively condensing or isolating dopaminergic neurons from undifferentiated cell population, there has been proposed a method of, introducing a reporter gene expressing a fluorescent protein under control of promoter/enhancer of a gene such as tyrosine hydroxylase (TH) expressed in dopaminergic neurons into each cell of the cell population, isolating the cells emitting fluorescence, and thereby visualizing the alive dopaminergic neurons to condense, segregate or identify (Japanese Patent Laid-Open Publication No. 2002-51775). However, this method requires a complex step of introduction of an exogenous gene, and furthermore, when used in gene treatment, the existence of the reporter gene causes problem of toxicity and immunogenicity.

[0009]

As described above, now, one of the largest problems in transplantation treatment for the Parkinson's disease is that the either dopaminergic neuron progenitor cells derived from the midbrain ventral region of aborted fetus or induced to differentiate are a mixture of various cells. It is desirable that only a desired cell species is isolated and used, considering safety in neural network formation. Furthermore, considering survival or ability for correctly forming a network in a brain in which the cells are transplanted, it can be said that it is desirable from the treatment effect that earlier proliferative progenitor cells are isolated and transplanted.

[0010]

Before now, as a gene that selectively expresses in the dopaminergic neuron proliferative progenitor cells, Lrp4 (WO 2004/065599) has been reported. Additionally, some markers of dopaminergic neuron progenitor cells have been reported (WO 2004/038018 and WO 2004/052190). Among them, with respect to Lmx1a, expression has been confirmed in human and mouse dopaminergic neuron proliferative progenitor cells, postmitotic dopaminergic neuron precursor cells, and dopaminergic neurons (WO 2005/052190).

[0011]

By the way, the Nato3 gene is a transcription factor having a basic helix-loop-helix (bHLH), and it has been reported that the Nato3 gene is expressed in the midbrain, and has an important role in the developmental process (Segev, E., N. Halachmi, A. Salzberg, and N. Ben-Arie. 2001. Mech Dev 106:197-202). Moreover, it has been reported that Nato3 is expressed in the midbrain, particularly, the most ventral side (floor plate), and relates to differentiation of neural cells (Verzi, M. P., J. P. Anderson, E. Dodou, K. K. Kelly, S.B. Greene, B. J. North, R. M. Cripps, and B. L. Black. 2002. Dev Biol 249:174-90).

[0012]

However, it is not reported that Nato3 is selectively expressed in dopaminergic neuron proliferative progenitor cells.

15 Summary of the Invention

[0013]

The present inventors have recently found that a Nato3 gene (hereinafter, occasionally referred to as merely "Nato3") is selectively expressed in dopaminergic neuron proliferative progenitor cells. The present invention is based on this finding.

[0014]

An object of the present invention is to provide a means for detecting a dopaminergic neuron proliferative progenitor cell, a method for detecting a dopaminergic neuron proliferative progenitor cell, and a kit for detecting a dopaminergic neuron proliferative progenitor cell.

[0015]

Further, an object of the present invention is to provide a method for screening for a substance effective for inducing differentiation into dopaminergic neuron proliferative progenitor cells.

[0016]

Furthermore, an object of the present invention is to provide a method for producing a dopaminergic neuron proliferative progenitor cell for use in the treatment of the Parkinson's disease.

[0017]

The present invention provides a polynucleotide probe or polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of a Nato3 gene, or a complementary sequence thereto (hereinafter, occasionally referred to as "probe according to the present invention" or "primer according to the present invention").

[0018]

The present invention provides an antibody against a Nato3 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell (hereinafter, occasionally referred to as "antibody according to the present invention").

[0019]

The present invention also provides a method for detecting or selecting a dopaminergic neuron proliferative progenitor cell, comprising the step of detecting expression of a Nato3 gene (hereinafter, occasionally referred to as "detection method according to the present invention").

[0020]

The present invention further provides a kit for detecting or selecting a dopaminergic neuron proliferative progenitor cell comprising at least a probe according to the present invention, a primer according to the present invention, or an antibody according to the present invention.

[0021]

The present invention provides a method for screening for a substance effective for inducing differentiation into a dopaminergic neuron proliferative progenitor cell, comprising the step of detecting expression of a Nato3 gene.

[0022]

The present invention provides a method for producing a dopaminergic neuron proliferative progenitor cell for use in the treatment of the Parkinson's disease.

[0023]

The present invention provides use of a polynucleotide that

64409-36

7

can hybridize with a polynucleotide consisting of a nucleotide sequence of a Nato3 gene, or a complementary sequence thereto, for detecting or selecting a dopaminergic neuron proliferative progenitor cell.

[0024] The present invention provides use of an antibody against a
5 Nato3 protein, or a part thereof, for detecting or selecting a dopaminergic neuron proliferative progenitor cell.

[0025] The probe according to the present invention, the primer according to the present invention, and the antibody according to the present invention can be utilized as selective markers for dopaminergic neuron proliferative progenitor cells.
10 Accordingly, the present invention is extremely useful in a purity test of a transplant material and development of a method for inducing differentiation into dopaminergic neuron proliferative progenitor cells in vitro, or the like, and is expected to contribute to the promotion of practical application of regenerative medicine.

Specifically, in one aspect, the invention relates to a polynucleotide
15 probe or polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which hybridizes under stringent conditions with a polynucleotide consisting of a nucleotide sequence of a Nato3 gene, or a complementary sequence thereto, wherein the stringent conditions comprise washing in 0.2xSSC, 0.1% SDS at 60°C to 65°C.

20 Other specific aspects of the invention include:

- an antibody that binds specifically to a Nato3 protein, or a part thereof, for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell;
- a method for detecting or selecting a dopaminergic neuron
25 proliferative progenitor cell, comprising the step of detecting expression of a Nato3 gene;
- a kit comprising at least the polynucleotide probe as described

64409-36

7a

herein and instructions for using the probe to detect or select a dopaminergic neuron proliferative progenitor cell;

5 - a kit comprising at least the polynucleotide primer as described herein or the polynucleotide primer set as described herein and instructions for using the primer to detect or select a dopaminergic neuron proliferative progenitor cell;

- a kit comprising at least the antibody as described herein and instructions for using the antibody to detect or select a dopaminergic neuron proliferative progenitor cell;

10 - a method for screening for an effective substance for inducing differentiation into a dopaminergic neuron proliferative progenitor cell, comprising the steps of: (i) contacting a cell that can differentiate into a dopaminergic neuron proliferative progenitor cell, with a substance to be tested; and (ii) detecting expression of a Nato3 gene in the cell contacted with the substance to be tested;

15 - a method for producing a dopaminergic neuron proliferative progenitor cell, comprising the steps of: (i) obtaining cells that can contain a dopaminergic neuron proliferative progenitor cell; (ii) detecting or selecting the dopaminergic neuron proliferative progenitor cell, by using the method as described herein; and (iii) culturing the cell detected or selected in step (ii);

20 - use of a polynucleotide that hybridizes under stringent conditions with a polynucleotide consisting of a nucleotide sequence of a Nato3 gene, or a complementary sequence thereto, for the detection or selection of a dopaminergic neuron proliferative progenitor cell, wherein the stringent conditions comprise washing in 0.2xSSC, 0.1% SDS at 60°C to 65°C; and

25 - use of an antibody that binds specifically to a Nato3 protein, or a part thereof, for the detection or selection of a dopaminergic neuron proliferative progenitor cell.

64409-36

7b

Brief Description of the Drawings

[0026] Figure 1 shows an expression period of dopaminergic neurons-related marker genes.

Figure 2 shows a midbrain of a 12.5-day mouse embryo. The midbrain is divided into four regions along the dorsoventral axis (V: most ventral region, VL: ventral lateral region, DL: dorsal lateral region, D: most dorsal region).

Figure 3 shows the results of analyzing, by the RT-PCR method, mRNA expression of *Nato3*, *DAT*, *Lmx1a* and *Lrp4* in each of the regions of the midbrain.

Figure 4 shows the results of analyzing, by *in situ* hybridization, mRNA expression of *Nato3*, *Nurr1*, and *TH* in the midbrain of an 11.5-day mouse embryo. Dotted lines represent a region in which dopaminergic neurons are generated, and dash lines represent borders between VZ (ventricular zone) and ML (mantle layer).

64409-36

8

Figure 5 shows the results of analyzing, by an immunostaining method, protein expression of *Nato3*, *Lmx1a* and *Nurr1*, and coexpression thereof (double staining) in the midbrain of an 11.5-day mouse embryo. Dotted lines represent a region in which dopaminergic neurons are generated, and dash lines represent borders between VZ (ventricular zone) and ML (mantle layer)

Figure 6 shows the results of analyzing, by the RT-PCR method, expressions of *Nato3* and other dopaminergic neuron marker genes in dopaminergic neuron progenitor cells induced to differentiate from ES cells.

Figure 7 shows separation of *Lrp4* positive cells and negative cells by a cell sorter.

Figure 8 shows the results of analyzing, by the RT-PCR method, expressions of *Nato3* and other dopaminergic neuron marker genes in each of the dopaminergic neuron proliferative progenitor cells separated from the cells derived from the midbrain of a 12.5-day mouse embryo (E12.5) and the SDIA differentiation induction cells.

20 Detailed Description of the Invention [0027]

Hereinafter, the present invention will be explained in detail. The following description is an example for explaining the present invention and the present invention is not limited to the embodiments to be described. All technical terms, scientific terms, and terminologies used in the present specification have the same meanings as those that are generally understood by those ordinary skilled in the art in the technical fields to which the present invention belongs and are used merely for the purpose of explanation of a specific embodiment but are not intended to make limitation. The present invention can be carried out in various embodiments as long as not departing from the spirit thereof. All the prior art documents, published publications, patent publications, and other patent documents, cited in the present specification, can be used for carrying out the present invention.

[0028]

[Dopaminergic Neuron Proliferative Progenitor Cell]

The "dopaminergic neuron proliferative progenitor cell", which is an object to be detected or selected in the present invention, means a dopaminergic neuron progenitor cell before
5 arrest of mitotic division.

[0029]

The dopaminergic neuron differentiates from a neuroepithelial cell, through the differentiation stages of a
10 proliferative progenitor cell and a postmitotic precursor cell, into a mature dopaminergic neuron. The dopaminergic neuron proliferative progenitor cell is the earliest progenitor cell in the dopaminergic neurons, and therefore, high survival rate and high ability of network formation in the brain to which the cell is
15 transplanted can be expected. Therefore, the dopaminergic neuron proliferative progenitor cell is useful for transplantation therapy for diseases caused by decrease in dopamine due to degeneration of the dopaminergic neurons such as the Parkinson's disease.

20 [0030]

The cells selected by using the probe, the primer, or the antibody according to the present invention as an index are dopaminergic neuron proliferative progenitor cells before arrest of mitotic division, and therefore, are preferable for the
25 transplantation treatment for neurodegenerative diseases such as the Parkinson's disease in the aspects of safety, survival rate, and network formation ability, compared to a conventional mixed cell population or dopaminergic neuron progenitor cells in which an exogenous gene is introduced. The cells are dopaminergic neuron
30 proliferative progenitor cells before arrest of mitotic division, namely, in proliferation, and have the possibility of differentiating to mature in the most appropriate place in the brain, and also, the dopaminergic neuron progenitor cells have the possibility of proliferating *in vivo*, and therefore, a longer effect of the treatment
35 can be expected. Therefore, it can be said that the present invention paves the way to the practical application of the effective

transplantation treatment of neurodegenerative diseases such as the Parkinson's disease.

[0031]

[Polynucleotide Probe and Polynucleotide Primer]

5 The probe and the primer according to the present invention can hybridize specifically with a Nato3 gene. As described above, the expression of a Nato3 gene is useful as an index of dopaminergic neuron proliferative progenitor cells. Therefore, the probe or the primer according to the present invention can be used
10 as a marker for detecting dopaminergic neuron proliferative progenitor cells.

[0032]

 The probe and the primer according to the present invention can be used for detecting expression of a Nato3 gene, and
15 corresponds to a polymer consisting of a plurality of bases or base pairs such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). It is known that double-strand cDNA can also be used in tissue *in situ* hybridization, and such double strand cDNA is included in the probe and the primer according to the present invention. As a
20 particularly preferable probe and primer in detection of RNA in tissue, an RNA probe (riboprobe) can be exemplified.

[0033]

 The probe and the primer according to the present invention includes those consisting of a polynucleotide comprising a sequence
25 of at least 10, preferably at least 15, more preferably at least 20, and further preferably at least 25 contiguous nucleotides of a nucleotide sequence of a Nato3 gene, or a complementary sequence thereto. Also, the probe and the primer according to the present invention includes those consisting of a polynucleotide
30 comprising a sequence of 10-50 or 10-30, 15-50 or 15-30, 20-50 or 20-30, and 25-50 or 25-30 contiguous nucleotides of a nucleotide sequence of a Nato3 gene, or a complementary sequence thereto.

[0034]

35 The probe and the primer according to the present invention can be at least 10 base length, preferably at least 15 base length,

more preferably at least 20 base length, further preferably at least 25 base length. The probe and the primer according to the present invention can also be 10-50 base length or 10-30 base length, 15-50 base length or 15-30 base length, 20-50 base length or 20-30 base length, and 25-50 base length or 25-30 base length.
5 [0035]

Preferable embodiments of the probe and the primer according to the present invention provide a probe and a primer having 15-30 base length for use in the detection or selection of a
10 dopaminergic neuron proliferative progenitor cell, consisting of a polynucleotide comprising a sequence of at least 10 (preferably at least 15, more preferably at least 20, and further preferably at least 25) contiguous nucleotides of a nucleotide sequence of a Nato3 gene, or a complementary sequence thereto, which can
15 hybridize with a Nato3 gene.

[0036]

Preferable embodiments of the probe and the primer according to the present invention provide those that can hybridize with a high discrimination part in the nucleotide sequence of a
20 Nato3 gene. By using such a probe and a primer, it becomes possible to detect the proliferative progenitor cells with higher accuracy. Such a probe and a primer include those that can hybridize with a nucleotide sequence comprising a part or all of a nucleotide sequence selected from the group consisting of
25 nucleotides 1-365 and 534-640 of SEQ ID NO:1, nucleotides 1-376 and 545-662 of SEQ ID NO:3, nucleotides 1-306 and 475-501 of SEQ ID NO:5, nucleotides 1-377 and 546-886 of SEQ ID NO:7, nucleotides 1-312 and 481-507 of SEQ ID NO:9, nucleotides 1-306 and 475-501 of SEQ ID NO:11, nucleotides 1-306 and 475-501 of
30 SEQ ID NO:13, nucleotides 1-177 and 346-372 of SEQ ID NO:15, nucleotides 1-359 and 528-557 of SEQ ID NO:17, nucleotides 1-357 and 523-552 of SEQ ID NO:19.

[0037]

The probe according to the present invention can be used as
35 a probe according to the general methods in known methods for detecting a gene of interest such as a northern blotting method, a

southern blotting method, an *in situ* hybridization method, and so forth.

[0038]

The probe according to the present invention can be chemically synthesized based on the nucleotide sequences disclosed in the present specification. The preparation of the probe is well-known and can be performed, for example, according to "Molecular Cloning, A Laboratory Manual 2nd ed." (Cold Spring Harbor Press (1989)) and "Current Protocols in Molecular Biology" (John Wiley & Sons (1987-1997)).

[0039]

The primer according to the present invention can also be used as a primer set consisting of two or more kinds of the primers.

[0040]

The primer and the primer set according to the present invention can be utilized as a primer and a primer set according to the general methods in known methods for detecting a gene of interest by utilizing a nucleic acid amplification method such as a PCR method, a RT-PCR method, a real-time PCR method, an *in situ* PCR method, or a LAMP method.

[0041]

The primer set according to the present invention can be selected so that the nucleotide sequence of a Nato3 gene can be amplified by a nucleic acid amplification method. Nucleic acid amplification methods are well-known, and selection of the primer pair in the nucleic acid amplification method is understood by those skilled in the art. For example, in the PCR method, primers can be selected so that one of the two primers (primer pair) is paired with the plus strand of the double strand DNA of a Nato3 gene, the other primer is paired with the minus strand of the double strand DNA, and with a strand extended by one primer, the other primer can be paired. Moreover, in the LAMP method (WO 00/28082), with respect to the target gene, three regions F3c, F2c, and F1c are defined from the 3' end side, and three regions B1, B2, and B3 are defined from the 5' end side, and by using the six regions, four

kinds of primers can be designed.

[0042]

The primer according to the present invention can be chemically synthesized based on the nucleotide sequences disclosed in the present specification. The preparation of the probe is well-known and can be performed, for example, according to "Molecular Cloning, A Laboratory Manual 2nd ed." (Cold Spring Harbor Press (1989)), "Current Protocols in Molecular Biology" (John Wiley & Sons (1987-1997)).

10 [0043]

In the present invention, the "Nato3 gene", which is an index of the existence of the dopaminergic neuron proliferative progenitor cell, is known in human, mouse, rat, chimpanzee, dog, bovine, chicken, and so forth. GenBank Accession Numbers disclosing the respective sequences are as follows.

[0044]

Nato3 Gene

Human: NM_152898 (SEQ ID NO:1 (base sequence), SEQ ID NO:2 (amino-acid sequence), hereinafter representation will be in the same order), AF517122 (SEQ ID NO:3, SEQ ID NO:4), BC069147(SEQ ID NO:5, SEQ ID NO:6), AF369897 (same as BC069147)

Mouse: NM_033522(SEQ ID NO:7, SEQ ID NO:8), AF517121(same as NM_033522), AF369896(SEQ ID NO:9, SEQ ID NO:10)

25 Rat: XM_345658(SEQ ID NO:11, SEQ ID NO:12)

Chimpanzee: XM_527676(SEQ ID NO:13, SEQ ID NO:14)

Dog: XM_539457(SEQ ID NO:15, SEQ ID NO:16)

Bovine: XM_584097(SEQ ID NO:17, SEQ ID NO:18)

Chicken: XM_425989(SEQ ID NO:19, SEQ ID NO:20)

30 Also with respect to an animal (preferably mammal) except for the above-described animals, those skilled in the art can specify a sequence of a Nato3 gene inherent in the animal, based on the known full-length sequence of a Nato3 gene. For example, by homology search based on the human or mouse Nato3 gene, a Nato3 gene of the animal can be searched and identified. In the homology search, BLAST to be described later or the like can be

35

used.

[0045]

The Nato3 gene includes:

5 a polynucleotide encoding a human Nato3 protein consisting of an amino acid sequence of at least one selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6;

a polynucleotide encoding a mouse Nato3 protein consisting of an amino acid sequence of at least one selected from the group consisting of SEQ ID NO:8 and SEQ ID NO:10;

10 a polynucleotide encoding a rat Nato3 protein consisting of an amino acid sequence of SEQ ID NO:12;

a polynucleotide encoding a chimpanzee Nato3 protein consisting of an amino acid sequence of SEQ ID NO:14;

15 a polynucleotide encoding a dog Nato3 protein consisting of an amino acid sequence of SEQ ID NO:16;

a polynucleotide encoding a bovine Nato3 protein consisting of an amino acid sequence of SEQ ID NO:18; and

a polynucleotide encoding a chicken Nato3 protein consisting of an amino acid sequence of SEQ ID NO:20.

20 [0046]

Moreover, the Nato3 gene includes:

a polynucleotide comprising a human Nato3 gene DNA sequence of at least one selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5;

25 a polynucleotide comprising a mouse Nato3 gene DNA sequence of at least one selected from the group consisting of SEQ ID NO:7 and SEQ ID NO:9;

a polynucleotide comprising a rat Nato3 gene DNA sequence of SEQ ID NO:11;

30 a polynucleotide comprising a chimpanzee Nato3 gene DNA sequence of SEQ ID NO:13;

a polynucleotide comprising a dog Nato3 gene DNA sequence of SEQ ID NO:15;

35 a polynucleotide comprising a bovine Nato3 gene DNA sequence of SEQ ID NO:17; and

a polynucleotide comprising a chicken Nato3 gene DNA

sequence of SEQ ID NO:19.

[0047]

The Nato3 gene according to the present invention includes genes encoding proteins which are functionally equivalent to a Nato3 protein. Whether the gene is "functionally equivalent" can be determined by evaluating a biological phenomenon or function relating to the expression of a Nato3 gene, for example, by evaluating whether the gene is selectively expressed in a dopaminergic neuron proliferative progenitor cell.

10 [0048]

Moreover, the proteins which are functionally equivalent to a Nato3 protein include proteins having polymorphism when the gene encoding the amino acid sequence (such as amino acid sequence of SEQ ID NO:2) has polymorphism.

15 [0049]

The gene encoding the proteins which are functionally equivalent to the Nato3 protein includes:

a gene encoding an amino acid sequence (modified amino acid sequence) of a Nato3 protein (for example, the amino acid sequence of SEQ ID NO:2 and the amino acid sequence of SEQ ID NO:8) in which one or more amino acid residues are inserted, substituted or deleted, or are added to one or both ends in the amino acid sequence;

a gene that can hybridize under stringent conditions with a gene encoding an amino acid sequence of a Nato3 protein (for example, the amino acid sequence of SEQ ID NO:2 and the amino acid sequence of SEQ ID NO:8) ; and

a gene encoding an amino acid sequence having at least an identity of 70% or more with an amino acid sequence of a Nato3 protein (for example, the amino acid sequence of SEQ ID NO:2 and the amino acid sequence of SEQ ID NO:8).

[0050]

In the present specification, "one or more amino acid residues are inserted, substituted or deleted, or are added to one or both ends in the amino acid sequence" means that the modification is performed by a well-known technical method such

as a site-directed mutagenesis or by substitution of a plurality of some amino acids to an extent of being naturally generated, or the like.

[0051]

5 The modified amino acid sequence of a Nato3 protein can be an amino acid sequence in which, for example, 1-30, preferably 1-20, more preferably 1-9, further preferably 1-5, and particularly preferably 1 or 2 amino acid(s) is/are inserted, substituted, or deleted, or is/are added to one or both of end(s) in amino acid
10 sequence. The modified amino acid sequence can be preferably an amino acid sequence having one or more (preferably, one or several, or 1, 2, 3 or 4) conservative substitutions in the amino acid sequence of the Nato3 protein.

[0052]

15 The term "conservative substitutions" means that one or more amino acid residues are substituted with other chemically analogous amino acid residues so as not to substantially change protein activity. For example, the case that a certain hydrophobic residue is substituted with another hydrophobic residue and the
20 case that a certain polar residue is substituted with another polar residue having the same charge can be exemplified. Functionally analogous amino acids which can be substituted in such a manner are known in the technical field, with respect to every amino acid. To give specific examples, the non-polar (hydrophobic) amino acid
25 includes alanine, valine, isoleucine, leucine, proline, tryptophan, phenylalanine, methionine. The polar (neutral) amino acid includes glycine, serine, threonine, tyrosine, glutamine, asparagines, cysteine. Positively charged (basic) amino acids include arginine, histidine, and lysine. Moreover, negatively
30 charged (acidic) amino acids include aspartic acid and glutamic acid.

[0053]

 In the present specification, "hybridize" means hybridization to a target polynucleotide under stringent conditions. Specifically,
35 there can be exemplified a polynucleotide having identity of at least 70% or more, preferably 80% or more, more preferably 85% or

more, further preferably 90% or more, further more preferably 95% or more, particularly preferably 98% or more, and most preferably 99% or more, with the target nucleotide sequence when calculation is performed using a parameter of default (initial setting) with homology search software such as FASTA, BLAST, Smith-Waterman [Meth. Enzym., 164, 765 (1988)]. Moreover, "under stringent conditions" can be performed according to a method of performing reaction in a hybridization buffer solution that can be generally used by those skilled in the art so that the temperature is 40-70°C, and preferably 60-65°C and performing rinsing in a rinse solution whose salt concentration is 15-300 mmol/L, and preferably 15-60 mmol/L. The temperature and the salt concentration can be appropriately adjusted according to length of the probe to be used. Furthermore, the condition when the hybridized nucleotide is rinsed can be 0.2 or 2xSSC, 0.1% SDS, and a temperature of 20-68°C. As to control of the stringent conditions (high stringency) or the mild condition (low stringency), the difference can be provided by salt concentration or temperature in rinsing. When the difference of the hybridization is provided by salt concentration, a stringent wash buffer (high stringency wash buffer) of 0.2xSSC and 0.1% SDS can be used, and a mild wash buffer (low stringency wash buffer) of 2xSSC and 0.1% SDS. Moreover, when the difference of the hybridization is provided by temperature, the temperature is 68°C in the stringent case, 42°C in the case of moderate stringency, and room temperature (20-25°C) in the mild case, and every case thereof may be performed under 0.2xSSC and 0.1% SDS.

[0054]

In general, the prehybridization is performed under the same conditions as the hybridization. However, hybridization and preliminary rinsing are not limited to be performed under the same conditions.

[0055]

The hybridization can be performed according to a known method. Moreover, in the case of using a commercially available library, the hybridization can be performed according to the method

64409-36

18

described in the appended instruction for use.

[0056]

In the present specification, the term "identity" (occasionally referred to as homology) with respect to amino acid sequences means the degree of identity of the amino acid residues of the respective sequences between the sequences to be compared. In this case, existence of a gap and property of the amino acid are considered (Wilbur, Natl. Acad. Sci. U.S.A. 80:726-730(1993)). For calculation of the homology, BLAST* (Altschul: J. Mol. Biol. 215:403-410 (1990)), FASTA (Pearson: Methods in Enzymology 183:63-69 (1990)), or the like can be used.

[0057]

The amino acid sequence having at least an identity of 70% or more with the amino acid sequence of a Nato3 protein can be an amino acid sequence having identity of preferably 80% or more, more preferably 85% or more, further preferably 90% or more, further more preferably 95% or more, particularly preferably 98% or more, and most preferably 99% or more.

[0058]

The "identity" may be a value calculated by using a homology search program known by those skilled in the art and can be calculated, for example, by using a parameter of default (initial setting) in the homology algorithm BLAST* (Basic local alignment search tool) in NCBI (National Center for Biotechnology Information).

25

[0059]

[Antibody]

The antibody according to the present invention can recognize specifically a Nato3 protein. As described above, the expression of a Nato3 gene is useful as an index for dopaminergic neuron proliferative progenitor cells. Therefore, the antibody according to the present invention can be used as a marker for detecting dopaminergic neuron proliferative progenitor cells.

[0060]

35 A Nato3 protein for obtaining the antibody according to the present invention may have antigenicity of Nato3 and includes a

*Trade-mark

protein in which one or more amino acid residues are deleted, inserted, substituted, or added in an amino acid sequence of a Nato3 protein. It is known that in such a protein, the same biological activity as the original protein is maintained (Mark et al. (1984) Proc. Natl. Acad. Sci. USA 81:5662-6; Zoller and Smith (1982) Nucleic Acids Res. 10:6487-500; Wang et al. (1984) Science 224:1431-3; and Dalbadie-McFarland et al. (1982) Proc. Natl. Acad. Sci. USA 79:6409-13). A method that one or more amino acid residues are deleted, inserted, substituted, or added in the state of maintaining the antigenicity of the original protein in a protein is known. For example, a polynucleotide encoding a mutant protein can be prepared by a site-directed mutagenesis and can be appropriately expressed (Molecular Cloning, A Laboratory Manual 2nd ed., Cold Spring Harbor Press (1989), Current Protocols in Molecular Biology, John Wiley & Sons (1987-1997); Sections 8.1-8.5; Hashimoto-Goto et al. (1995) Gene 152:271-5; Kinkel (1985) Proc. Natl. Acad. Sci. USA 82:488-92; Kramer and Fritz (1987) Method. Enzymol. 154:350-67; and Kunkel (1988) Method. Enzymol. 85:2763-6).

20 [0061]

The antibody according to the present invention includes an antibody specific to a part of a Nato3 protein. Specifically, a Nato3 protein for obtaining an antibody of the present invention includes a polypeptide fragment having at least 6 amino acid residues or more (for example, 6, 8, 10, 12, or 15 amino acid residues or more) of the Nato3 protein, as well as a polypeptide having a full-length amino acid sequence. The polypeptide fragment of the Nato3 protein in the present specification includes every fragment as long as the fragment has antigenicity of the Nato3 protein.

30 [0062]

The preferable fragment includes polypeptide fragments such as the amino terminal or the carboxyl terminal of the Nato3 protein. The antigenic determinant site of the polypeptide is estimated by a method of analyzing hydrophobicity/hydrophilicity of the amino acid sequence of the protein (Kyte-Doolittle(1982) J. Mol. Biol. 157:105-22) or a method of analyzing the secondary

structure (Chou-Fasman (1978) Ann. Rev. Biochem. 47:251-76), and furthermore, confirmed by a computer program (Anal. Biochem. 151:540-6 (1985)) or a technique such as a PEPSCAN method (Japanese Patent Laid-Open Publication No. 60-500684) of synthesizing a short peptide and confirming the antigenicity.

[0063]

The antibody against the Nato3 protein includes:

an antibody against a protein having an amino acid sequence of at least one selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6, or a part thereof;

an antibody against a protein having an amino acid sequence of at least one selected from the group consisting of SEQ ID NO:8 and SEQ ID NO:10, or a part thereof;

an antibody against a protein having an amino acid sequence of SEQ ID NO:12, or a part thereof;

an antibody against a protein having an amino acid sequence of SEQ ID NO:14, or a part thereof;

an antibody against a protein having an amino acid sequence of SEQ ID NO:16, or a part thereof;

an antibody against a protein having an amino acid sequence of SEQ ID NO:18, or a part thereof; and

an antibody against a protein having an amino acid sequence of SEQ ID NO:20, or a part thereof.

[0064]

Preferable embodiments of the antibody according to the present invention provide an antibody recognizing a high discrimination polypeptide portion in a Nato3 protein. By using such an antibody, it becomes possible that the proliferative progenitor cells can be detected with higher accuracy. Such antibody includes an antibody against a high discrimination polypeptide portion in a Nato3 protein, for example, at least 6 amino acid residues or all of an amino acid sequence selected from a group consisting of amino acids 1-102 and 159-166 of SEQ ID NO:2, amino acids 1-102 and 159-166 of SEQ ID NO:4, amino acids 1-102 and 159-166 of SEQ ID NO:6, amino acids 1-104 and 161-168 of SEQ ID NO:8, amino acids 1-104 and 161-168 of SEQ

ID NO:10, amino acids 1-102 and 159-166 of SEQ ID NO:12, amino acids 1-102 and 159-166 of SEQ ID NO:14, amino acids 1-59 and 116-123 of SEQ ID NO:16, amino acids 1-101 and 158-164 of SEQ ID NO:18, amino acids 1-119 and 176-183 of SEQ
5 ID NO:20.

[0065]

The antibody according to the present invention can also be obtained by using a well-known method for those skilled in the art (for example, "Current Protocols in Molecular Biology" (John Wiley & Sons (1987) and Antibodies: A Laboratory Manual, Ed. Harlow and David Lane, Cold Spring Harbor Laboratory (1988)).
10

[0066]

The antibody according to the present invention includes a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a
15 single-strand antibody (scFv), a humanized antibody, a polyspecific antibody, and antibody fragments such as Fab, Fab', F(ab')₂, Fc, and Fv.

[0067]

In the case of the polyclonal antibody, the blood of a mammal in which an antigen is sensitized is extracted and serum is segregated from the blood by a known method to serve as the serum containing the polyclonal antibody.
20

[0068]

According to need, fractions containing the polyclonal antibodies can also be further isolated.
25

[0069]

In the case of the monoclonal antibody, antibody-producing cells obtained from the spleen or the lymph node of a mammal in which the above-described antigen is sensitized are extracted and
30 cell-fused with myeloma cells. The obtained hybridoma is cloned and the antibody is collected from the culture to serve as the monoclonal antibody.

[0070]

As the immunizing antigen, a fragment of the Nato3 protein can be used. Alternatively, an antigen synthesized based on the above-described amino acid sequence can be used. The antigen
35

may be used as a complex with a carrier protein. For preparation of the complex of the antigen and the carrier protein, various condensation agents such as glutaraldehyde, carbodiimide, maleimide-activated ester, or the like can be used. The carrier
5 protein may be one generally used such as bovine serum albumin, thyroglobulin, hemocyanin, or the like and is generally performed coupling at a ratio of 1-5.

[0071]

The animal to be immunized includes mouse, rat, rabbit,
10 guinea pig, and hamster. The injection method includes subcutaneous, muscular, or intraperitoneal administration. In the administration, the antigen may be mixed with complete Freund's adjuvant or incomplete Freund's adjuvant. The administration is generally performed one time per 2-5 weeks.

15 [0072]

The antigen-producing cells obtained from the spleen or the lymph node of the immunized animal is cell-fused with myeloma cells and isolated as hybridomas. The myeloma cells derived from mouse, rat, or human are used, and are preferably derived from
20 the same species as the antigen-producing cells, but cells between different species are occasionally possible.

[0073]

The cell fusion can be performed according to a previously known method, for example, the method disclosed in Nature, 256,
25 495, 1975.

[0074]

The fusion accelerator includes polyethylene glycol or Sendai virus, and in general, the cell fusion can be performed by reaction for approximately 1-10 minutes so that the ratio of the number of
30 the antigen-producing cells and the number of the myeloma cells is generally approximately 1:1-10:1, under a temperature of 20-40°C, and preferably 30-37°C by using polyethylene glycol (average molecular weight 1000-4000) having a concentration of approximately 20-50%.

35 [0075]

For the screening of the antigen-producing hybridoma,

various immunochemical methods can be used. For example, an ELISA method in which a microplate on which the Nato3 protein is coated is used, an EIA method in which a microplate on which an anti-immunoglobulin antibody is coated is used, and an immunoblotting method in which a nitrocellulose transfer membrane is used after electrophoresing samples containing the Nato3 protein.

[0076]

From such wells, further cloning is performed by, for example, a limiting dilution method, and thereby, clones can be obtained. Selection and breeding of hybridomas are generally performed in a medium for animal cells (for example, RPMI1640) containing 10-20% bovine embryo serum to which HAT (hypoxanthine, aminopterin, and thymidine) is added. The clones obtained as described above are transplanted into the abdominal cavity of a SCID mouse to which pristine is preliminarily administered, and ascitic fluid containing the monoclonal antibody at high concentration is collected after 10-14 days to serve as a material for antibody purification. Also, the clones can be cultured and the culture can be a material for antibody purification.

[0077]

For the purification of the monoclonal antibody, a previously known method may be used as the purification method of immunoglobulin, and the purification can be easily achieved, for example, by an ammonium sulfate fraction method, a PEG fraction method, an ethanol fraction method, utilization of an anion exchanger, affinity chromatography in which a Nato3 protein is used, or the like.

[0078]

The purification of the polyclonal antibody from the serum can be performed similarly.

[0079]

[Detection Method]

The expression of a Nato3 gene serves as an index of the existence of dopaminergic neuron proliferative progenitor cells. Therefore, according to the present invention, by detecting

expression of a Nato3 gene, the dopaminergic neuron proliferative progenitor cells can be detected or selected.

[0080]

5 The method for "detecting expression of a Nato3 gene" used herein is not particularly limited as long as being capable of detecting the expression of a Nato3 gene in the cell samples to be tested, and, for example, includes hybridization methods, nucleic acid amplification methods, and antigen-antibody reaction methods.

10 [0081]

The "cell samples to be tested" used herein can be cell samples that are thought to contain the dopaminergic neuron proliferative progenitor cells, and the cells in the midbrain ventral region can be used. The cells in the midbrain ventral region can be obtained by a known method (Studer, L., et al. Nature Neurosci (1998) 1:290-295). Preferably, fetus' (preferably, human aborted fetus') or the patient's own cells of the midbrain ventral region can be used as the cell samples to be tested. Moreover, the culture cells containing dopaminergic neuron proliferative progenitor cells induced to differentiate *in vitro* can be used as the cell samples to be tested. The induction to differentiate into the dopaminergic neuron proliferative progenitor cells *in vitro* can be performed by the differentiation treatment by a known method such as an SDIA method (Kawasaki et al. Neuron (2000) 28(1):31-40) or a 5-stage method (Lee, SH., et al. Nature Biotech (2000) 18:675-579) by using, as a starting material, known ES cells (Kawasaki et al. Neuron (2000) 28(1):31-40 and Lee, SH., et al. Nature Biotech (2000) 18:675-579), bone marrow stromal cells, immortalized cell line derived from nerve (Japanese Patent Laid-Open Publication No. 8-509215, No. 11-506930, and No. 2002-522070), neuron primordial cells (Japanese Patent Laid-Open Publication No. 11-509729), or the like. Preferably, ES cells subjected to the differentiation treatment by the SDIA method can be used as the cell samples to be tested.

35 [0082]

The "SDIA method" used herein can be performed by

co-culturing the ES cells and the stromal cell line PA6 in a serum-free medium (Kawasaki et al. Neuron (2000) 28(1):31-40). Moreover, the "5-stage method" can be performed as follows. ES cells are cultured on a non-adherent culture plate under existence
5 of the serum and thereby an embryoid body (EB) is formed, and sequentially, the EB is attached onto an adherent culture plate, and thereby, the neuron progenitor cells are selected. Finally, a growth factor such as Shh, FGF2, or FGF8 is added thereto, and thereby, dopaminergic neuron progenitor cells are induced (Lee, SH., et al.
10 Nature Biotech (2000) 18:675-579).

[0083]

According to the first embodiment of the detection method according to the present invention, the probe according to the present invention hybridizes with a nucleic acid sample (mRNA or
15 transcript thereof), and the hybridization complex, namely, nucleotide double strand, is detected. Thus, the expression of the Nato3 gene can be detected in the cell samples.

[0084]

For the detailed procedure of the hybridization method,
20 there can be referred to "Molecular Cloning, A Laboratory Manual 2nd ed." (Cold Spring Harbor Press (1989), particularly Sections 9.47-9.58, "Current Protocols in Molecular Biology" (John Wiley & Sons (1987-1997)), particularly, Sections 6.3 and 6.4, "DNA Cloning 1: Core Techniques, A Practical Approach 2nd ed." (Oxford
25 University (1995), particularly, Section 2.10 for the conditions).

[0085]

The detection of expression of the Nato3 gene by utilizing the hybridization method can be performed, for example, by the following steps of:

- 30 (a) contacting a polynucleotide derived from a cell sample to be tested, with the polynucleotide probe according to the present invention; and
(b) detecting a hybridization complex.

[0086]

35 In step (a), mRNA prepared from the cell sample to be tested that is thought to contain dopaminergic neuron proliferative

progenitor cells or complementary DNA (cDNA) transcribed from the mRNA, as the polynucleotide derived from the cell sample to be tested, can be contacted with the probe.

[0087]

5 In the detection method by using a probe, the probe can be labeled. The label includes a label by utilizing radioactivity (such as ^{32}P , ^{14}C , and ^{35}S), fluorescence (such as FITC, europium), an enzyme (such as peroxidase or alkaline phosphatase) reaction such as chemical coloring, or the like.

10 [0088]

The detection of the hybridization product can be performed by using a well-known method such as northern hybridization, southern hybridization, or colony hybridization.

15 [0089]

The cells in which the hybridization complex is detected are those expressing a Nato3 gene, and therefore can be determined as the dopaminergic neuron proliferative progenitor cells.

[0090]

20 According to the second embodiment of the detection method according to the present invention, the expression of the Nato3 gene can be detected in the cell sample by amplifying nucleic acid samples (mRNA or transcript thereof) by a nucleic acid amplification method using the primer or primer set according to
25 the present invention, and detecting the amplification product is detected.

[0091]

The detection of expression of the Nato3 gene by utilizing the nucleic acid amplification method can be performed, for
30 example, by the following steps of:

(c) performing a nucleic acid amplification method by using a polynucleotide derived from a cell sample to be tested as a template and the polynucleotide primer or the polynucleotide primer set according to the present invention; and

35 (d) detecting a formed amplification product.

[0092]

In step (c), mRNA prepared from the cell sample to be tested that is thought to contain dopaminergic neuron proliferative progenitor cells or complementary DNA (cDNA) transcribed from the mRNA can be used as the template.

5 [0093]

The detection of the amplification product can be performed by using a nucleic acid amplification method such as a PCR method, a RT-PCR method, a real-time PCR method, or a LAMP method.

[0094]

10 The cells in which the amplification product is detected are also expressing a Nato3 gene, and therefore can be determined as the dopaminergic neuron proliferative progenitor cells.

[0095]

15 According to the third embodiment of the detection method according to the present invention, the antibody according to the present invention and the cell sample are contacted, and the antigen-antibody reaction is detected. Thus, the expression of a Nato3 gene can be detected in the cell sample.

[0096]

20 The detection of expression of the Nato3 gene by utilizing the antigen-antibody reaction can be performed, for example, by the following steps of:

(e) contacting a protein derived from a cell sample to be tested, with the antibody according to the present invention;

25 and

(f) measuring an antigen-antibody complex.

[0097]

30 The method for detecting the antigen-antibody reaction is well-known for the skilled person, and, for example, a Nato3 protein can be detected in the cell sample to be tested that is thought to contain dopaminergic neuron proliferative progenitor cells by an immunological method. For the immunological method, a previously known method such as a immunohistologic staining method, an enzyme-linked immunosorbent assay, a western blotting method, an agglutination method, a competition method,
35 or a sandwich method, can be applied to the cell sample subjected

to appropriate treatment according to need, such as segregation or extraction operation of the cells. The immunohistologic staining method can be performed by, for example, a direct method by using a labeled antibody or an indirect method by using an labeled antibody against the antibody. For the labeling agent, a known labeling substance such as a fluorescent substance, a radioactive substance, an enzyme, a metal, or a pigment can be used.

[0098]

The cells in which the antigen-antibody complex is detected are those expressing a Nato3 gene, and therefore can be determined as the dopaminergic neuron proliferative progenitor cells.

[0099]

For use in the treatment of the Parkinson's disease, it is desirable that the purity of the dopaminergic neuron proliferative progenitor cells is high.

[0100]

The accuracy of the detection or selection of the dopaminergic neuron proliferative progenitor cells can be enhanced by performing each of the above-described detection steps not only once but repeatedly.

[0101]

Therefore, according to the detection method according to the present invention, the dopaminergic neuron proliferative progenitor cells can be detected or selected with high accuracy by performing the above-described step twice or more.

[0102]

Moreover, the accuracy of detection or selection of the dopaminergic neuron proliferative progenitor cells can be enhanced by using together other marker genes, preferably dopaminergic neuron proliferative progenitor cell marker genes except for the Nato3 genes.

[0103]

Therefore, according to the detection method according to the present invention, the dopaminergic neuron proliferative progenitor cells can be detected or selected with higher accuracy

by using together dopaminergic neuron proliferative progenitor cell marker genes except for the Nato3 genes, postmitotic dopaminergic neuron precursor cell marker genes or the like, and detecting not only expression of the Nato3 gene but also
5 expression of the other above-described marker genes .

[0104]

The dopaminergic neuron-related marker genes expressing selectively in each of the differentiation stages are shown in Figure 1.

10 [0105]

In the detection method characterized in that the expression of the Nato3 gene is detected, the dopaminergic neuron proliferative progenitor cells can be detected or selected with high accuracy by detecting not only the Nato3 gene but also the
15 dopaminergic neuron proliferative progenitor cell marker gene except for the Nato3 genes by using together dopaminergic neuron proliferative progenitor cell marker gene except for the Nato3 genes.

[0106]

20 Specifically, in step (a), step (c), or step (e), the dopaminergic neuron proliferative progenitor cells can be detected or selected with high accuracy by using the cells in which the expression of the dopaminergic neuron proliferative progenitor cell marker gene except for the Nato3 genes is detected as the cell
25 sample to be tested. In this case, the cells in which the hybridization complex is detected in the step (b), the cells in which the amplification product is detected in the step (d), and the cells in which the antigen-antibody complex is detected in the step (f) each express a Nato3 gene, and the dopaminergic neuron
30 proliferative progenitor cell marker gene except for the Nato3 genes. Thus, the cells can be determined as the detected or selected dopaminergic neuron proliferative progenitor cells with high accuracy.

[0107]

35 Moreover, the dopaminergic neuron proliferative progenitor cells can be detected or selected with high accuracy by performing

step (g-1) of detecting expression of the dopaminergic neuron proliferative progenitor cell marker gene except for the Nato3 genes with respect to the cells in which the hybridization complex is detected in step (b), the cells in which the amplification product is detected in step (d), and the cells in which the antigen-antibody complex is detected in step (f), respectively. In this case, in step (g-1), the cells in which the expression of the dopaminergic neuron proliferative progenitor cell marker gene except for the Nato3 genes is detected are those expressing a Nato3 gene, and the dopaminergic neuron proliferative progenitor cell marker gene except for the Nato3 genes. Thus, the cells can be determined as the detected or selected dopaminergic neuron proliferative progenitor cells with high accuracy.

[0108]

15 In the detection method characterized in that the expression of the Nato3 gene is detected, by using together a postmitotic dopaminergic neuron precursor cell marker gene, it can be confirmed that the Nato3 gene is expressed but the expression of the postmitotic dopaminergic neuron precursor cell marker gene is not detected. Thus, the dopaminergic neuron proliferative precursor cells can be detected or selected with high accuracy.

[0109]

Specifically, in step (a), step (c), or step (e), the dopaminergic neuron proliferative progenitor cells can be detected or selected with high accuracy by using the cells in which the expression of the postmitotic dopaminergic neuron precursor cell marker gene is not detected. In this case, the cells in which the hybridization complex is detected in step (b), the cells in which the amplification product is detected in step (d), and the cells in which the antigen-antibody complex is detected in step (f) each express a Nato3 gene but does not express the postmitotic dopaminergic neuron precursor cell marker gene. Thus, the cells can be determined as the detected or selected dopaminergic neuron proliferative progenitor cells with high accuracy.

35 [0110]

Moreover, the dopaminergic neuron proliferative progenitor

cells can be detected or selected with high accuracy by performing step (g-2) of detecting expression of the postmitotic dopaminergic neuron precursor cell marker gene with respect to the cells in which the hybridization complex is detected in step (b), the cells in which the amplification product is detected in step (d), and the cells in which the antigen-antibody complex is detected in step (f), respectively. In this case, in step (g-2), the cells in which the expression of the postmitotic dopaminergic neuron precursor cell marker gene is not detected are those expressing a Nato3 gene, but not the postmitotic dopaminergic neuron precursor cell marker gene. Thus, the cells can be determined as the detected or selected dopaminergic neuron proliferative progenitor cells with high accuracy.

[0111]

"The dopaminergic neuron proliferative progenitor cell marker gene except for the Nato3 genes " includes a dopaminergic neuron proliferative progenitor cell marker gene except for a Nato3 gene which is expressed in the midbrain's most ventral ventricular region (VZ region), and includes an Lrp4 gene, an Msx1 gene, an Msx2 gene, and a Mash1 gene.

[0112]

An Lrp4 gene is described in WO 2004/065599. A Mash1 gene is described in Kele J, Simplicio N, Ferri AL, Mira H, Guillemot F, Arenas E, Ang SL. Neurogenin 2 is required for the development of ventral midbrain dopaminergic neurons, and Development. 2006 Feb; 133(3):495-505. It has been confirmed by the present inventors that an Msx1 gene and an Msx2 gene are expressed selectively in the dopaminergic neuron proliferative progenitor cells (the data not shown).

[0113]

The detection of the dopaminergic neuron proliferative progenitor cell marker gene except for the Nato3 genes is not limited as long as using a method by which expression of the known gene can be detected, and, for example, includes the above-described hybridization method, the nucleic acid amplification method, and the antigen-antibody reaction method.

[0114]

“The postmitotic dopaminergic neuron precursor cell marker gene” includes a gene expressed in the midbrain’s most ventral mantle layer (ML region), and includes a Nurr1 gene, an En1 gene,
5 an En2 gene, a Ptx3 gene, and a TH gene. Moreover, the marker gene includes a gene expressed in the midbrain’s most ventral ventricular region (VZ region), and includes a 65B13 gene.

[0115]

A Nurr1 gene is described in Science. 1997 11;
10 276(5310):248-50. An En1 gene is described in J. Neurosci. 2001
21(9): 3126-34. An En2 gene is described in J. Neurosci. 2001
21(9) 3126-34. A Ptx3 gene is described in Proc. Natl. Acad. Sci.
1997 94: 13305-10. A TH gene is described in Science 1997 11;
276(5310):248-50. A 65B13 gene is described in WO
15 2004/038018.

[0116]

The detection of the postmitotic dopaminergic neuron precursor cell marker gene is not particularly limited as long as using a method by which expression of the known gene can be
20 detected, and, for example, includes the above-described hybridization method, the nucleic acid amplification method, and the antigen-antibody reaction method.

[0117]

[Detection Kit]

25 The present invention provides a detection kit for performing the detection method according to the present invention.

[0118]

The first embodiment of the detection kit according to the
30 present invention includes a detection kit for performing the detection method of the first embodiment according to the present invention, and specifically, a kit for detecting the expression of the Nato3 gene, including at least the probe according to the present invention. The probe may be labeled. The detection kit detects
35 the expression of the Nato3 gene by a hybrid formation method.

[0119]

Therefore, the detection method of the first embodiment can optionally further include various reagents for performing the hybrid formation method such as a substrate compound used for detection of the marker, hybridization buffer, instructions, equipment, and/or so forth.

[0120]

For performing the detection with high accuracy, the detection kit of the first embodiment according to the present invention may further include the probe, the primer, the primer set, or the antibody which can detect the expression of the dopaminergic neuron proliferative progenitor cell marker gene except for the Nato3 genes, or the expression of the postmitotic dopaminergic neuron precursor cell marker gene. The probe, the primer, the primer set, or the antibody may be labeled. By any of the hybrid formation method, the nucleic acid amplification method, and the antigen-antibody reaction method, the detection kit further detects the expression of the dopaminergic neuron proliferative progenitor cell marker gene except for the Nato3 genes, or the expression of the postmitotic dopaminergic neuron precursor cell marker gene.

[0121]

The second embodiment of the detection kit according to the present invention includes a detection kit for performing the detection method of the second embodiment according to the present invention, and specifically, a kit for detecting the expression of the Nato3 gene, including at least the primer according to the present invention or the primer set according to the present invention. The detection kit detects the expression of the Nato3 gene by the nucleic acid amplification method.

[0122]

Therefore, the detection method of the second embodiment can optionally further include various reagents for performing the nucleic acid amplification method such as a buffer, an internal standard indicating that the PCR can normally progress, instructions, equipment, and/or so forth.

[0123]

For performing the detection with high accuracy, the detection kit of the second embodiment according to the present invention may further include the probe, the primer, the primer set, or the antibody which can detect the expression of the
5 dopaminergic neuron proliferative progenitor cell marker gene except for the Nato3 genes, or the expression of the postmitotic dopaminergic neuron precursor cell marker gene. The probe, the primer, the primer set, or the antibody may be labeled. By any of the hybrid formation method, the nucleic acid amplification method,
10 and the antigen-antibody reaction method, the detection kit further detects the expression of the dopaminergic neuron proliferative progenitor cell marker gene except for the Nato3 genes, or the expression of the postmitotic dopaminergic neuron precursor cell marker gene.

15 [0124]

The third embodiment of the detection kit according to the present invention includes a detection kit for performing the detection method of the third embodiment according to the present invention, and specifically, a kit for detecting the expression of the
20 Nato3 gene, including at least the antibody according to the present invention. The antibody may be labeled. The detection kit detects the expression of the Nato3 gene by detecting the antigen-antibody reaction.

[0125]

25 Therefore, the detection method of the third embodiment can optionally further include various reagents for performing the antigen-antibody reaction such as a secondary antibody used for the ELISA method or the like, a coloring reagent, a buffer, instructions, equipment, and/or so forth.

30 [0126]

For performing the detection with high accuracy, the detection kit of the third embodiment according to the present invention may further include the probe, the primer, the primer set, or the antibody which can detect the expression of the
35 dopaminergic neuron proliferative progenitor cell marker gene except for the Nato3 genes, or the expression of the postmitotic

dopaminergic neuron precursor cell marker gene. The probe, the primer, the primer set, or the antibody may be labeled. By any of the hybrid formation method, the nucleic acid amplification method, and the antigen-antibody reaction method, the detection kit further
5 detects the expression of the dopaminergic neuron proliferative progenitor cell marker gene except for the Nato3 genes, or the expression of the postmitotic dopaminergic neuron precursor cell marker gene.

[0127]

10 [Screening method]

The detection method according to the present invention can be applied to screening for effective substances for inducing differentiation into the dopaminergic neuron proliferative progenitor cells. Specifically, effective substances for inducing differentiation
15 into dopaminergic neuron proliferative progenitor cells can be screened for by determining whether or not the addition of a substance to be tested has induced the differentiation into the dopaminergic neuron proliferative progenitor cells using expression of a Nato3 gene as an index.

20 [0128]

Therefore, the present invention provides a method for screening for an effective substance for inducing differentiation into a dopaminergic neuron proliferative progenitor cell, comprising the following steps of:

- 25 (i) contacting a cell that can differentiate into a dopaminergic neuron proliferative progenitor cell, with a substance to be tested; and
(ii) detecting expression of a Nato3 gene in the cell contacted with the substance to be tested.

30 [0129]

The cell that can differentiate into a dopaminergic neuron proliferative progenitor cell in step (i) can be preferably collected from an embryonic midbrain ventral region or from culture cells containing neuron progenitor cells induced to differentiate from ES
35 cells.

[0130]

"Contacting with a substance to be tested" in step (i) can be performed by, for example, adding the substance to be tested to culture cells containing the cells that can differentiate into a dopaminergic neuron proliferative progenitor cell.

5 [0131]

"Substance to be tested" includes a synthesized low-molecular compound, a protein, a synthesized peptide, a purified or partially purified polypeptide, an antibody, a bacterium-releasing material (comprising bacterial metabolite), and
10 a nucleic acid (such as antisense, ribozyme, and RNAi), and is preferably a synthesized low-molecular compound, but is not limited thereto. "Substance to be tested" may be a novel substance or a known substance.

[0132]

15 In step (ii), according to the detection method of the present invention, the expression of the Nato3 gene can be detected.

[0133]

Specifically, steps (a) and (b) are performed for the
20 detection by utilizing the hybridization method. Steps (c) and (d) are performed for the detection by utilizing the nucleic acid amplification method. Steps (e) and (f) are performed for the detection by utilizing the antigen-antibody reaction. Thus, the expression of the Nato3 gene can be detected.

25 [0134]

In step (ii), when the expression of the Nato3 gene is detected in the cell sample by contacting the substance to be tested, the substance can be determined as the effective substance for inducing differentiation into the dopaminergic neuron
30 proliferative progenitor cells.

[0135]

The substance specified by the screening method according to the present invention can be used as the effective substance for inducing differentiation into the dopaminergic neuron proliferative
35 progenitor cells.

[0136]

The present invention provides the method for screening for an effective substance for inducing differentiation into a dopaminergic neuron proliferative progenitor cell, further comprising the step of:

- 5 (iii) detecting expression of the dopaminergic neuron proliferative progenitor cell marker gene except for the Nato3 genes.

[0137]

10 When the expression of the Nato3 gene is detected in step (ii) and the expression of the dopaminergic neuron proliferative progenitor cell marker gene except for the Nato3 genes is detected in step (iii), the substance can be determined as the effective substance for inducing differentiation into dopaminergic neuron proliferative progenitor cells, with high accuracy.

15 [0138]

Step (iii) may be performed after step (i) and may be performed before or after the step (ii).

[0139]

20 "The dopaminergic neuron proliferative progenitor cell marker gene except for the Nato3 genes" includes the dopaminergic neuron proliferative progenitor cell marker gene except for the Nato3 genes that are expressed in the midbrain most ventral ventricular region (VZ region), and, for example, includes an Lrp4 gene, an Msx1 gene, an Msx2 gene, and a Mash1
25 gene.

[0140]

The detection of the dopaminergic neuron proliferative progenitor cell marker gene except for the Nato3 genes is not particularly limited as long as using a method by which the
30 expression of the known gene can be detected, for example, includes the above-described hybridization method, the nucleic acid amplification method, and the antigen-antibody reaction method.

[0141]

[Production Method]

35 The detection method according to the present invention can detect or select the dopaminergic neuron proliferative

progenitor cells. The dopaminergic neuron proliferative progenitor cells for use in the treatment of the Parkinson's disease. Therefore, the dopaminergic neuron proliferative progenitor cells for use in the treatment of the Parkinson's disease can be produced from the detected or selected dopaminergic neuron proliferative progenitor cells using the expression of a Nato3 gene as an index.

[0142]

The present invention provides a method for producing a dopaminergic neuron proliferative progenitor cell, comprising the steps of:

- (iv) obtaining cells that can contain a dopaminergic neuron proliferative progenitor cell;
- (v) detecting or selecting the dopaminergic neuron proliferative progenitor cell by using the detection method according to the present invention; and
- (vi) culturing the cell detected or selected in step (v).

[0143]

The present invention provides a method for treating the Parkinson's disease comprising the step of transplanting the dopaminergic neuron proliferative progenitor cells detected or selected by the detection method according to the present invention, or the dopaminergic neuron proliferative progenitor cells produced by the production method according to the present invention, into a mammal including a human.

[0144]

According to the treatment method of the present invention, the transplanted dopaminergic neuron proliferative progenitor cells produce dopamine, and thus, the Parkinson's disease can be prevented and/or treated.

[0145]

When the treatment method according to the present invention is performed, the cells that can contain the dopaminergic neuron proliferative progenitor cells can be collected from a mammal comprising a human, and preferably, the individual subjected to the transplantation or an aborted fetus.

[0146]

64409-36

39

The dopaminergic neuron proliferative progenitor cells can be transplanted into a brain, preferably, a midbrain.

[0147]

In the present specification, "detection" includes
5 "discrimination".

Examples

[0148]

Hereinafter, the present invention will be specifically
10 explained by Examples, but the following Examples do not limit the scope of the present invention.

[0149]

[Example 1] Expression Analysis of Nato3 Gene

(1) Analysis by RT-PCR Method

15 In order to confirm that a Nato3 gene is expressed in the cells of dopaminergic neuron lineage, expressions of mRNAs of Nato3, DAT, Lmx1a, and Lrp4 in each region of a mouse embryonic midbrain were investigated by a RT-PCR method according to the following protocol. Here, DAT is a marker gene of the
20 dopaminergic neuron (Development. 2004; 131(5):1145-55.), Lmx1a is a marker gene of dopaminergic neurons and dopaminergic neuron progenitor cells (WO2005/052190), and Lrp4 is a marker gene of the dopaminergic neuron proliferative progenitor cells (WO2004/065599).

25 [0150]

From a 12.5-day mouse (obtained from SLC) embryo, 4 regions (V region: most ventral region, VL region: ventral lateral region, DL region: dorsal lateral region, and D region: most dorsal region) of the midbrain shown in Figure 2 were cut out, and the
30 total RNA was prepared by using a RNeasy^{*} mini kit (Qiagen), and double-strand cDNA was synthesized by using a cDNA synthesis kit (TAKARA). Next, the synthesized cDNA was digested with the restriction enzyme RsaI (TAKARA), and then, ad2 was added thereto, and PCR was performed at 15 cycles using ad2S as a
35 primer, and thereby, cDNA was amplified and used as a template for RT-PCR. The amplification was carried out under the conditions

*Trade-mark

64409-36

40

that incubation was performed for 5 minutes at 72°C, and then reactions for 30 seconds at 94°C, for 30 seconds at 65°C, and for 2 minutes at 72°C, were performed at 15 cycles, and finally, incubation was performed for 2 minutes at 72°C.

5 ad2S: cagctccacaacctacatcattccgt (SEQ ID NO:21)
 ad2A: acggaatgatgt (SEQ ID NO:22)

[0151]

10 Next, by using the cDNAs corresponding to the amplified
cDNA of 4 ng, 0.4 ng, and 0.04 ng as templates, PCR was performed in the following reaction system.

	10xExTaq*	1 µl
	2.5 mM dNTP	0.8 µl
	ExTaq*	0.05 µl
15	100 µM primer	0.1 µl for each
	cDNA	1 µl
	Distilled water	6.95 µl

20 After incubation for 2 minutes at 94°C, the amplification
reaction for 30 seconds at 94°C, for 30 seconds at 65°C, and for 2
minutes at 72°C, was performed, and finally, incubation was
performed for 2 minutes at 72°C. The PCR amplifications were
performed at 26 cycles for Lrp4, DAT and Lmx1a, and at 25 cycles
for Nato3.

[0152]

25 The following primers were used in the PCR.

Lrp4: tagtctaccactgctcgactgtaacg (SEQ ID NO:23)
 cagagtgaaccagtgacatatctg (SEQ ID NO:24)
DAT: cagaatcctgtgctcacggtagttgc (SEQ ID NO:25)
 actaaagtggctgcaagctgaccagg (SEQ ID NO:26)
30 Lmx1a:tggttcaggtgtggttccagaaccag (SEQ ID NO:27)
 tctgagggtgccaggaagcagtctcc (SEQ ID NO:28)
Nato3:cctgggaagactgtcgcagtttgatg (SEQ ID NO:29)
 gaaggcctcgtttaggttgaacatcc (SEQ ID NO:30)

35 [0153]

As a result, it became revealed that mRNA of Nato3 is

*Trade-mark

selectively expressed in the V region of the midbrain in which the marker genes of dopaminergic neuron and dopaminergic neuron progenitor cells are expressed (Figure 3).

[0154]

5 (2) Analysis by *in situ* Hybridization

Furthermore, in order to investigate the expression pattern in detail, by *in situ* hybridization according to the following protocol, expression analysis of mRNA of *Nato3*, *Nurr1*, and tyrosine hydroxylase (TH) was performed. *Nurr1* and TH are marker genes that are known to be induced to express first after postmitotic in the dopaminergic neuron precursor cells (Science. 1997 11; 276(5310):248-50.).

[0155]

First, a DIG-probe was produced by the following method.

15 From a 12.5-day mouse (obtained from SLC) embryo, the midbrain afterbrain region was cut out, and the total RNA was prepared by using the RNeasy mini kit (Qiagen), and double-strand cDNA was synthesized by using the cDNA synthesis kit (TAKARA). By using the synthesized cDNA as a template, cDNAs of *Nato3*, *Nurr1*, and TH were amplified in the following reaction system.

20	10xExTaq	5 μ l
	2.5 mM dNTP	4 μ l
	ExTaq	0.25 μ l
	100 μ M primer	0.5 μ l for each
25	cDNA	1 μ l
	Distilled water	38.75 μ l

The amplification was carried out under the conditions that incubation was performed for 5 minutes at 94°C, and then reactions for 30 seconds at 94°C, for 30 seconds at 65°C, and for 2 minutes at 72°C, were performed at 35 cycles, and finally, incubation was performed for 2 minutes at 72°C.

[0156]

The following primers were used in the PCR.

35 *Nato3*: atcggcagctatgccattcctgcaag (SEQ ID NO:31)
 tgctccaagcaagaagctctaactcc (SEQ ID NO:32)
 TH: gctgtcacgtccccaagggttcattgg (SEQ ID NO:33)

ggagcgcagtagtaagatgtgg (SEQ ID NO:34)
 Nurr1:catatgatcgagcagaggaagacacc (SEQ ID NO:35)
 agtgcaacaccgtagtgctgacagg (SEQ ID NO:36)

5 [0157]

The amplified cDNA fragments were cloned into pCRII (Invitrogen) and used as templates, and thereby, DIG-probes were synthesized by the following reaction system (all of the reagents were purchased from Roche)

10	RNA Polymerase Buffer	2 μ l
	NTP Labeling Mix	2 μ l
	RNase Inhibitor	1 μ l
	RNA polymerase (T7 or SP6)	2 μ l
	Template DNA	1 μ g
15	Distilled water	Total 20 μ l

After 2 hours at 37°C, DNaseI (Roche) treatment was performed for 15 minutes at 37°C, and the DIG-RNA probe was collected by ethanol precipitation.

[0158]

20 Next, an 11.5-day mouse embryo was excised and fixed for 2 hours at 4°C by using 4% PFA (WAKO)/PBS (-), and then, the solution was replaced at 4°C overnight by 20% sucrose (WAKO)/PBS (-) and then the embryo was embedded with OCT (Sakura Seiki Co., Ltd.). Sections of 12 μ m thickness were
 25 prepared and dried on slide glasses and then fixed again for 30 minutes at room temperature by using 4% PFA. After rinsing with PBS, hybridization (1 μ g/ml DIG-RNA probe, 50% formamide (Nacalai Tesque, Inc.), 5xSSC, 1% SDS, 50 μ g/ml yeast RNA (Sigma), 50 μ g/ml heparin) was performed for 40 hours at 68°C.
 30 Then, rinsing (50% formamide, 5xSSC, and 1%SDS) was performed at 68°C and further rinsing (50% formamide, 5xSSC) was performed at 68°C. After rinsing with 1xTBST at room temperature, blocking (blocking agent: Roche) was performed. Alkaline phosphatase-labeled anti-DIG antibody (DAKO) was
 35 reacted at 4°C overnight, and after rinsing (1xTBST, 2mM levamisole), NBT/BCIP (DAKO) was used as the substrate for

coloring.

[0159]

As a result, in the 11.5-day mouse embryo which is in the period of generating dopaminergic neurons, it became revealed that mRNA of Nato3 is strongly expressed in the V region in the same manner as TH and Nurr1 (Figure 4). Also, by contrast that mRNA of TH and Nurr1 is expressed only in the mantle layer (ML) region in which the postmitotic neurons exist, it became revealed that mRNA of Nato3 is not expressed in the ML region but is expressed only in the ventricular zone (VZ) in which the proliferative progenitor cells exist (Figure 4). From the above-described results, it became revealed that mRNA of Nato3 is selectively and strongly expressed in the dopaminergic neuron proliferative progenitor cells.

15 [0160]

[Example 2] Expression Analysis of Nato3 Protein

Next, by using anti-Nato3 antibody, the expression of Nato3 protein was studied. Moreover, double staining by using an anti-Lmx1a antibody and an anti-Nurr1 antibody was performed.

20 [0161]

First, the 1-92 amino acid region of Nato3 protein was expressed as a fusion protein with a GST protein in E. Coli JM109 cell line (TAKARA) and collected. A rat was immunized with the collected fusion protein, and then, a lymphocyte cell was taken out and cell-fused to a myeloma P3U1, and thereby, an anti-Nato3 antibody-producing hybridoma was obtained (hybridoma production was outsourced to Kojin-Bio Co., Ltd.). Similarly, the 271-307 amino acid region of the Lmx1a protein was expressed as a fusion protein with the GST protein and collected. A hamster (obtained from SLC) was immunized with the collected fusion protein, and then, the lymphocyte cells were taken out and cell-fused to a myeloma (ATCC), and thereby, an anti-Lmx1a antibody-producing hybridoma was obtained.

35 [0162]

A 11.5-day mouse embryo was excised and fixed for 2 hours

64409-36

44

at 4°C by using 4% PFA (WAKO)/PBS (-), and then, the solution was replaced at 4°C overnight by 20% sucrose (WAKO)/PBS (-) and then the embryo was embedded with OCT (Sakura Seiki Co., Ltd.). Sections of 12 µm thickness were prepared, mounted on slide glasses, dried for 30 minutes at room temperature, and then moistened again with PBS (-). Next, blocking (Blockase (Dainippon Sumitomo Pharma Co., Ltd.)) was performed for 30 minutes at room temperature, and then, reaction with a primary antibody (anti-Nato3 and anti-Lmx1a antibodies from above-described hybridoma culture supernatant, anti-Nurr1 antibody from Santa Cruz) was performed for one hour at room temperature, and then, reaction was further performed at 4°C overnight. By using 0.1% Tween-20/PBS (-), rinsing was performed for 15 minutes at room temperature three times. Next, a fluorescence-labeled secondary antibody (Jackson) was reacted for one hour at room temperature and rinsing was performed in the same manner, and then, rinsing with PBS(-) was performed for 10 minutes at room temperature, and sealed.

[0163]

As a result, it became revealed that Nato3 is expressed in the midbrain of the 11.5-day mouse embryo as protein as well as mRNA (Figure 5). From the result of double staining with anti-Lmx1a antibody and anti-Nurr1 antibody, it was confirmed that Nato3 protein is co-expressed with the Lmx1a protein, and thus it became revealed that the Nato3 protein is expressed selectively in the dopaminergic neuron proliferative progenitor cells (Figure 5). Moreover, it was confirmed that the Nato3 protein is expressed selectively in the VZ region in which a Nurr1 protein is not expressed, and thus it became revealed that the Nato3 protein is expressed selectively in the dopaminergic neuron proliferative progenitor cells (Figure 5).

[0164]

[Example 3] Expressions of Nato3 Gene in Dopaminergic Neurons Induced to Differentiate from ES Cells

Whether a Nato3 gene is expressed when ES cells are induced to differentiate into dopaminergic neurons was studied.

*Trade-mark

[0165]

First, according to the SDIA method (Kawasaki et al. Neuron. 2000 28(1):31-40.), ES cells (mouse CCE strain provided from Mr. Nishikawa in Riken CDB, Kawasaki et al. Neuron. 2000 28(1):31-40.) was induced to differentiate into dopaminergic neurons. The cells were collected after 4, 6, 8, 10, 12 days after the induction. The total RNA was prepared by using the RNeasy mini kit (Qiagen), and RT-PCR was performed. First, with respect to 1 µg of the total RNA, cDNA synthesis was performed by using the RNA PCR kit (TAKARA). By using the cDNAs corresponding to 10 ng, 1 ng, and 0.1 ng as templates, PCR was performed in the following reaction system.

	10xExTaq	2 µl
	2.5 mM dNTP	1.6 µl
15	ExTaq	0.1 µl
	100 µM primer	0.2 µl for each
	cDNA	1 µl
	Distilled water	14.9 µl

After incubation for 2 minutes at 94°C, the reaction for 30 seconds at 94°C, for 30 seconds at 65°C, and for 2 minutes at 72°C, was performed at 35 cycles, and finally, incubation was performed for 2 minutes at 72°C.

[0166]

The following primers were used in the PCR.

25 TH: gttccaaggaaagtgtcagagttgg (SEQ ID NO:37)
gaagctggaaagcctccagggtgttcc (SEQ ID NO:38)
DAT: ctccgagcagacacccatgaccttagc (SEQ ID NO:39)
aggagtagggcttgtctcccaacctg (SEQ ID NO:40)
Nurr1: cactcctgtgtctagctgccagatgc (SEQ ID NO:41)
30 agtgcgaacaccgtagtgctgacagg (SEQ ID NO:42)
Ptx3: tgagccgcaggctgtggatccatcc (SEQ ID NO:43)
tccctgttctggccttagtcctagg (SEQ ID NO:44)
En1: atcctccgagtggacattcacatagg (SEQ ID NO:45)
atgtccagcaaatagagatcgctacac (SEQ ID NO:46)

35 In addition, for Nato3 and Lmx1a, the primers of Example 1 were used. Moreover, Ptx3 and En1 are known as markers of the

postmitotic dopaminergic neuron precursor cells.

[0167]

As a result, expression of mRNA of *Nato3* was not recognized in ES cells (CCE) and stromal cells (PA6), but it became
5 revealed that as a result of the differentiation induction, the expression is induced from the fourth day in the same manner as *Lmx1a*, which is a marker gene of the dopaminergic neuron proliferative progenitor cells (Figure 6).

[0168]

10 [Example 4] Expression of *Nato3* Gene in Dopaminergic Neuron Proliferative Progenitor Cells Sorted by *Lrp4*

In order to confirm that a *Nato3* gene is expressed in the dopaminergic neuron proliferative progenitor cells, the dopaminergic neuron proliferative progenitor cells were separated
15 from the cells derived from the midbrain of a 12.5-day mouse embryo and SDIA differentiation induction cells respectively using a *Lrp4* gene which is expressed selectively in the dopaminergic neuron proliferative progenitor cells as a marker, and the expression of mRNA of *Nato3* in these cells was investigated.

20 [0169]

First, a gene sequence encoding the extracellular region (161-502 amino acids) in an *Lrp4* gene was gene-transfected into 293E cells (ATCC), and the extracellular region of the *Lrp4* protein was expressed and collected. A hamster (obtained from SLC) was
25 immunized with the collected protein, and then, lymphocytic cells were extracted and cell-fused with myeloma cells (ATCC) to obtain an anti-*Lrp4* antibody-producing hybridoma.

[0170]

The group of the cells containing the dopaminergic neuron
30 progenitor cells derived from the midbrain of the 12.5-day mouse embryo or induced to differentiate from ES cells *in vitro* was dispersed by using a cell dissociation bufferTM (Invitrogen), and then, without being subjected to fixation and permeabilization treatments, the cells were stained for 20 minutes at 4°C by using
35 an anti-*Lrp4* monoclonal antibody (a culture supernatant diluted to 1/2, 1% fetal bovine serum (JRH), 1mM EDTA/SDIA differentiation

medium (Kawasaki et al. Neuron (2000)28(1):31-40)). Then, with 1% fetal bovine serum and 1mM EDTA/SDIA differentiation medium, rinsing was performed for 3 minutes at 4°C three times, and the cells were stained for 20 minutes at 4°C by using a
 5 biotin-labeled anti-hamster IgG antibody (Jackson, 10 µg/ml, 1% fetal bovine serum, 1mM EDTA/SDIA differentiation medium), and then, rinsing was performed in the same manner. The cells were stained for 20 minutes at 4°C by using a PE-labeled streptavidin
 10 (Pharmingen, 20 µg/ml, 1% fetal bovine serum, 1mM EDTA/SDIA differentiation medium), and then, rinsing was performed in the same manner. After the staining, Lrp4 positive cells and negative cells were separated by a cell sorter (FACS vantage SE, Becton Dickinson) (Figure 7). The total RNA was prepared from the cells immediately after the separation, by using the RNeasy mini kit
 15 (Qiagen), and the double stand cDNA was synthesized by using the cDNA synthesis kit (TAKARA). After digestion with restriction enzyme RsaI (TAKARA), ad2 was added thereto, and ad2S was used as a primer, and the cDNA was amplified by PCR of 15 cycles and used for the template for RT-PCR. The amplification was
 20 carried out under the conditions that incubation was performed for 5 minutes at 72°C, and then reactions for 30 seconds at 94°C, for 30 seconds at 65°C, and for 2 minutes at 72°C, were performed at 15 cycles, and finally, incubation was performed for 2 minutes at 72°C.

25 [0171]

Next, by using the cDNAs corresponding to the amplified cDNA of 4 ng, 0.4 ng, and 0.04 ng as templates, PCR was performed in the following reaction system.

30	10xExTaq	1 µl
	2.5 mM dNTP	0.8 µl
	ExTaq	0.05 µl
	100 µM primer	0.1 µl for each
	cDNA	1 µl
	Distilled water	6.95 µl

35 The primers having the above-described sequences were used.

[0172]

After incubation for 2 minutes at 94°C, the amplification reaction for 30 seconds at 94°C, for 30 seconds at 65°C, and for 2 minutes at 72°C, was performed, and finally, incubation was performed for 2 minutes at 72°C. The amplifications of PCR were performed at 24 cycles for Lmx1a and Nurr1 and at 26 cycles for the other.

[0173]

As a result, in the cells derived from the midbrain of the 12.5-day mouse embryo, mRNA of Nato3 was strongly expressed in a Lrp4-positive cell population (namely, dopaminergic neuron proliferative progenitor cells) (Figure 8). Also, in the SDIA differentiation induction cells, mRNA of Nato3 was strongly expressed in the Lrp4-positive cell population (Figure 8). Accordingly, it was revealed that mRNA of Nato3 is expressed in the dopaminergic neuron proliferative progenitor cell, in the SDIA differentiation induction cells as well as in the cells derived from the mouse embryonic midbrain.

[0174]

Therefore, it was revealed that a Nato3 gene is a useful marker for discriminating not only the dopaminergic neuron proliferative progenitor cells derived from the embryonic midbrain but also the dopaminergic neuron proliferative progenitor cells induced to differentiate from ES cells *in vitro*.

48a

The sequences in the sequence listing in electronic form are reproduced in the following table.

SEQUENCE TABLE

<110> Eisai R&D Management Co., Ltd.

<120> Dopaminergic neuron proliferation progenitor cell marker Nato3

<130> 159836PX

<160> 46

<170> PatentIn version 3.1

<210> 1

<211> 640

<212> DNA

<213> Homo sapiens

<400> 1

```

accagcaacc tcgcccctcc ctgcggaaaa ccgatgagag gcagggccaa gccgaagcga      60
tggcggccta tccggagagc tgcgtggaca ctacggtgct ggacttcgtc gcagacctgt      120
ccctggcctc cccgagacgc cctctcctct gcgacttcgc acccggggtc tccttggggg      180
accagccct tgcgctccga gaggaagac ccaggaggat ggcgcggttt gaagaggggg      240
accagaaga agaggagtgc gaagtggacc agggggacgg agaagaggag gaggaagagg      300
agcgcggaag aggtgtctcc ctattaggcc gccccaagag gaaaagggtg atcacctacg      360
cccagcgcca ggccgccaac atccgcgaaa ggaagcggat gttcaacctc aacgaggcct      420
ttgaccagct gcggaggaag gtgcccacgt ttgcttacga gaaaaggctg tcccggatcg      480
agaccctccg cctggccatc gtctatatct ccttcatgac cgagctcttg gagagctgtg      540
agaagaagga aagcggctga gcctgggtgtg gagagtctgc ccttcctcgt ctggtagtgc      600
tggggtgtgt caggaccggg cactgggtga ggctaaaggg      640

```

<210> 2

<211> 166

<212> PRT

<213> Homo sapiens

<400> 2

```

Met Ala Ala Tyr Pro Glu Ser Cys Val Asp Thr Thr Val Leu Asp Phe
1           5           10           15
Val Ala Asp Leu Ser Leu Ala Ser Pro Arg Arg Pro Leu Leu Cys Asp
          20           25           30

```

48b

Phe Ala Pro Gly Val Ser Leu Gly Asp Pro Ala Leu Ala Leu Arg Glu
 35 40 45
 Gly Arg Pro Arg Arg Met Ala Arg Phe Glu Glu Gly Asp Pro Glu Glu
 50 55 60
 Glu Glu Cys Glu Val Asp Gln Gly Asp Gly Glu Glu Glu Glu Glu
 65 70 75 80
 Glu Arg Gly Arg Gly Val Ser Leu Leu Gly Arg Pro Lys Arg Lys Arg
 85 90 95
 Val Ile Thr Tyr Ala Gln Arg Gln Ala Ala Asn Ile Arg Glu Arg Lys
 100 105 110
 Arg Met Phe Asn Leu Asn Glu Ala Phe Asp Gln Leu Arg Arg Lys Val
 115 120 125
 Pro Thr Phe Ala Tyr Glu Lys Arg Leu Ser Arg Ile Glu Thr Leu Arg
 130 135 140
 Leu Ala Ile Val Tyr Ile Ser Phe Met Thr Glu Leu Leu Glu Ser Cys
 145 150 155 160
 Glu Lys Lys Glu Ser Gly
 165

<210> 3
 <211> 662
 <212> DNA
 <213> Homo sapiens

<400> 3
 gaattcggct taccagcaac ctgcgccctc cctgcggaaa accgatgaga ggcagggcca 60
 agccgaagcg atggcggcct atccggagag ctgcgtggac actacggtgc tggacttcgt 120
 cgcagacctg tccttggcct ccccgagacg ccctctctc tgcgacttcg caccgggggt 180
 ctcttggggg gaccagccc ttgcgctccg agagggaaga cccaggagga tggcgcggtt 240
 tgaagagggg gaccagaag aagaggagtg cgaagtggac cagggggacg gagaagagga 300
 ggaggaagag gagcgcggaa gaggtgtctc cctattaggc cgcccccaaga ggaaaagggt 360
 gatcacctac gccagcgc ccaggcccaa catccgcgaa aggaagcggg tgttcaacct 420
 caacgaggcc tttgaccagc tgcggaggaa ggtgccacg tttgcttacg agaaaaggct 480
 gtcccggatc gagaccctcc gcctggccat cgtctatata tccttcatga ccgagctctt 540
 ggagagctgt gagaagaagg aaagcggctg agcctgggtg ggagagtctg cccttctctg 600
 tctggtagtg ctgggggtg tcaggaccgg gcaactgggtg aggctaaagg gaagccgaat 660
 tc 662

48c

<210> 4
 <211> 166
 <212> PRT
 <213> Homo sapiens

<400> 4
 Met Ala Ala Tyr Pro Glu Ser Cys Val Asp Thr Thr Val Leu Asp Phe
 1 5 10 15
 Val Ala Asp Leu Ser Leu Ala Ser Pro Arg Arg Pro Leu Leu Cys Asp
 20 25 30
 Phe Ala Pro Gly Val Ser Leu Gly Asp Pro Ala Leu Ala Leu Arg Glu
 35 40 45
 Gly Arg Pro Arg Arg Met Ala Arg Phe Glu Glu Gly Asp Pro Glu Glu
 50 55 60
 Glu Glu Cys Glu Val Asp Gln Gly Asp Gly Glu Glu Glu Glu Glu
 65 70 75 80
 Glu Arg Gly Arg Gly Val Ser Leu Leu Gly Arg Pro Lys Arg Lys Arg
 85 90 95
 Val Ile Thr Tyr Ala Gln Arg Gln Ala Ala Asn Ile Arg Glu Arg Lys
 100 105 110
 Arg Met Phe Asn Leu Asn Glu Ala Phe Asp Gln Leu Arg Arg Lys Val
 115 120 125
 Pro Thr Phe Ala Tyr Glu Lys Arg Leu Ser Arg Ile Glu Thr Leu Arg
 130 135 140
 Leu Ala Ile Val Tyr Ile Ser Phe Met Thr Glu Leu Leu Glu Ser Cys
 145 150 155 160
 Glu Lys Lys Glu Ser Gly
 165

<210> 5
 <211> 501
 <212> DNA
 <213> Homo sapiens

<400> 5
 atggcggcct atccggagag ctgcgtggac actacggtgc tggacttcgt cgcagacctg 60
 tccttggcct ccccgagacg ccctctctc tgcgacttcg caccgggggt ctccttgggg 120
 gaccagccc ttgcgctccg agagggaaga cccaggagga tggcgcggtt tgaagagggg 180
 gaccagaag aagaggagtg cgaagtggac cagggggacg gagaagagga ggaggaagag 240
 gagcgcggaa gaggtgtctc cctattagge cgccccaaga ggaaaagggt gatcacctac 300
 gccagcgcg ccaggcccaa catccgcgaa aggaagcgga tgttcaacct caacgaggcc 360
 tttgaccagc tgcggaggaa ggtgcccacg tttgcttacg agaaaaggct gtcccggatc 420

48d

gagaccctcc gcctggccat cgtctatatc tccttcatga ccgagctctt ggagagctgt 480
 gagaagaagg aaagcggctg a 501

<210> 6
 <211> 166
 <212> PRT
 <213> Homo sapiens

<400> 6
 Met Ala Ala Tyr Pro Glu Ser Cys Val Asp Thr Thr Val Leu Asp Phe
 1 5 10 15
 Val Ala Asp Leu Ser Leu Ala Ser Pro Arg Arg Pro Leu Leu Cys Asp
 20 25 30
 Phe Ala Pro Gly Val Ser Leu Gly Asp Pro Ala Leu Ala Leu Arg Glu
 35 40 45
 Gly Arg Pro Arg Arg Met Ala Arg Phe Glu Glu Gly Asp Pro Glu Glu
 50 55 60
 Glu Glu Cys Glu Val Asp Gln Gly Asp Gly Glu Glu Glu Glu Glu Glu
 65 70 75 80
 Glu Arg Gly Arg Gly Val Ser Leu Leu Gly Arg Pro Lys Arg Lys Arg
 85 90 95
 Val Ile Thr Tyr Ala Gln Arg Gln Ala Ala Asn Ile Arg Glu Arg Lys
 100 105 110
 Arg Met Phe Asn Leu Asn Glu Ala Phe Asp Gln Leu Arg Arg Lys Val
 115 120 125
 Pro Thr Phe Ala Tyr Glu Lys Arg Leu Ser Arg Ile Glu Thr Leu Arg
 130 135 140
 Leu Ala Ile Val Tyr Ile Ser Phe Met Thr Glu Leu Leu Glu Ser Cys
 145 150 155 160
 Glu Lys Lys Glu Ser Gly
 165

<210> 7
 <211> 886
 <212> DNA
 <213> Mus musculus

<400> 7
 accaaggagc tctatcggca gctatgccat tcctgcaaga aaatcgggtga gatagacgct 60
 gagtgatggc cgcctatcca gagagctgct tggatgctac cgtgctgaac ttcgtagcag 120
 atctctctct ggctctccc agacaccctc ttctctgcga gttcccacct ggggtccctt 180
 ttggggaccg aacactgggg tacagagagg gaagacctgg gagactgtcg cagtttgatg 240
 aaagatatca ggaagtagag ggggacgaag tggaatatga ggaccagaa gaggaggaag 300

48e

```

aggagggaga ggggcgcggc agagtagcat ccttgctggg ccgccccaaa agaaaaagag 360
ttattactta tgcccagcgc caggccgcca acattcgcga gaggaagagg atgttcaacc 420
taaacgagggc cttcgaccag ctgvcgagaa aggtacccac cttcgcttat gagaagagac 480
tgtcgaggat cgagaccctc cgcttggcca tcgtctacat ttccttcatg accgagctcc 540
tgcagagcaa ggaggaaaag gaggccagct gagcggggag gggtgagccc aagagacact 600
ccccgcctc atcgtgcttg gcgggggtgcg tctggaaggc agaggggccc ctggccttct 660
gaggcggggg ttgagatggg aaactcccca ctvcgvcgag ctctvcagtg aataagttgg 720
ggatccggca caataagggt ctagctgggc aggttgggag ttcccggggg caaggattta 780
gggagttaga gcttcttgct tggagcaggt gggaaactgg tctgctcctc cacggacctc 840
tggtgatctc tcctccttgc tccttttcaa cagtagaaat aataaa 886

```

```

<210> 8
<211> 168
<212> PRT
<213> Mus musculus

```

```

<400> 8
Met Ala Ala Tyr Pro Glu Ser Cys Leu Asp Ala Thr Val Leu Asn Phe
1          5          10          15
Val Ala Asp Leu Ser Leu Ala Ser Pro Arg His Pro Leu Leu Cys Glu
20          25          30
Phe Pro Pro Gly Val Pro Phe Gly Asp Arg Thr Leu Gly Tyr Arg Glu
35          40          45
Gly Arg Pro Gly Arg Leu Ser Gln Phe Asp Glu Arg Tyr Gln Glu Val
50          55          60
Glu Gly Asp Glu Val Glu Tyr Glu Asp Pro Glu Glu Glu Glu Glu
65          70          75          80
Gly Glu Gly Arg Gly Arg Val Ala Ser Leu Leu Gly Arg Pro Lys Arg
85          90          95
Lys Arg Val Ile Thr Tyr Ala Gln Arg Gln Ala Ala Asn Ile Arg Glu
100         105         110
Arg Lys Arg Met Phe Asn Leu Asn Glu Ala Phe Asp Gln Leu Arg Arg
115         120         125
Lys Val Pro Thr Phe Ala Tyr Glu Lys Arg Leu Ser Arg Ile Glu Thr
130         135         140
Leu Arg Leu Ala Ile Val Tyr Ile Ser Phe Met Thr Glu Leu Leu Gln
145         150         155         160
Ser Lys Glu Glu Lys Glu Ala Ser
165

```


48f

<210> 9
 <211> 507
 <212> DNA
 <213> Mus musculus

<400> 9
 atggccgcct atccagagag ctgcttggat gctaccgtgc tgaacttcgt agcagatctc 60
 tctctggcct ctcccagaca ccctcttctc tgcgagttcc cacctggggg cctttttggg 120
 gaccgaacac tgggggtacag agaggggaaga cctgggagac tgtcgcagtt tgatgaaaga 180
 tatcaggaag tagaggggga cgaagtggaa tatgaggacc cagaagagga ggaagaggag 240
 ggagagggggc gcggcagagt agcatccttg ctggggccgcc ccaaagaaa aagagttatt 300
 acttatgccc agcgcagggc cgccaacatt cgcgagagga agaggatggt caacctaaac 360
 gaggccttcg accagctgcg cagaaaggta cccaccttcg cttatgagaa gagactgtcg 420
 aggatcgaga ccctccgctt ggccatcgtc tacatttctt tcatgaccga gctcctgcag 480
 agcaaggagg aaaaggaggc cagctga 507

<210> 10
 <211> 168
 <212> PRT
 <213> Mus musculus

<400> 10
 Met Ala Ala Tyr Pro Glu Ser Cys Leu Asp Ala Thr Val Leu Asn Phe
 1 5 10 15
 Val Ala Asp Leu Ser Leu Ala Ser Pro Arg His Pro Leu Leu Cys Glu
 20 25 30
 Phe Pro Pro Gly Val Pro Phe Gly Asp Arg Thr Leu Gly Tyr Arg Glu
 35 40 45
 Gly Arg Pro Gly Arg Leu Ser Gln Phe Asp Glu Arg Tyr Gln Glu Val
 50 55 60
 Glu Gly Asp Glu Val Glu Tyr Glu Asp Pro Glu Glu Glu Glu Glu
 65 70 75 80
 Gly Glu Gly Arg Gly Arg Val Ala Ser Leu Leu Gly Arg Pro Lys Arg
 85 90 95
 Lys Arg Val Ile Thr Tyr Ala Gln Arg Gln Ala Ala Asn Ile Arg Glu
 100 105 110
 Arg Lys Arg Met Phe Asn Leu Asn Glu Ala Phe Asp Gln Leu Arg Arg
 115 120 125
 Lys Val Pro Thr Phe Ala Tyr Glu Lys Arg Leu Ser Arg Ile Glu Thr
 130 135 140
 Leu Arg Leu Ala Ile Val Tyr Ile Ser Phe Met Thr Glu Leu Leu Gln
 145 150 155 160

48g

Ser Lys Glu Glu Lys Glu Ala Ser
165

<210> 11
<211> 501
<212> DNA
<213> Rattus norvegicus

<400> 11
atggccgcct atccagagag ctgcttggac gctaacgtgc tgaacttcgt agcagatctc 60
tctctggcct ctcccagaca cccttttctc tgcgagttcc cacctggggg cccttttgag 120
gaccaaacac tgggggttcag agaaggaagg gggctgttgc agtttgaggg aagataccag 180
gaagtagagg ggggagaagt ggactatgag gacccggaag aggaggaaga ggagggagag 240
gggcgcggcc gagtagcatc cttgctgggc cgccccaaaa ggaaaagagt catcacttat 300
gccagcgc ccaggcccaa cattcgcgag agaaagagga tgtttaacct aaacgaggcc 360
ttcgaccagc tgcgcaggaa ggtgcccacc ttcgcttatg agaagaggct gtccaggatc 420
gagaccctcc gcttggccat cgtctacatt tctttcatga ccgagctcct gcagagcaag 480
gaggaaaagg aggccagctg a 501

<210> 12
<211> 166
<212> PRT
<213> Rattus norvegicus

<400> 12
Met Ala Ala Tyr Pro Glu Ser Cys Leu Asp Ala Asn Val Leu Asn Phe
1 5 10 15
Val Ala Asp Leu Ser Leu Ala Ser Pro Arg His Pro Phe Leu Cys Glu
20 25 30
Phe Pro Pro Gly Val Pro Phe Glu Asp Gln Thr Leu Gly Phe Arg Glu
35 40 45
Gly Arg Gly Leu Leu Gln Phe Glu Gly Arg Tyr Gln Glu Val Glu Gly
50 55 60
Gly Glu Val Asp Tyr Glu Asp Pro Glu Glu Glu Glu Glu Gly Glu
65 70 75 80
Gly Arg Gly Arg Val Ala Ser Leu Leu Gly Arg Pro Lys Arg Lys Arg
85 90 95
Val Ile Thr Tyr Ala Gln Arg Gln Ala Ala Asn Ile Arg Glu Arg Lys
100 105 110
Arg Met Phe Asn Leu Asn Glu Ala Phe Asp Gln Leu Arg Arg Lys Val
115 120 125

48h

Pro Thr Phe Ala Tyr Glu Lys Arg Leu Ser Arg Ile Glu Thr Leu Arg
 130 135 140

Leu Ala Ile Val Tyr Ile Ser Phe Met Thr Glu Leu Leu Gln Ser Lys
 145 150 155 160

Glu Glu Lys Glu Ala Ser
 165

<210> 13
 <211> 501
 <212> DNA
 <213> Pan troglodytes

<400> 13
 atggcggcct atccggagag ctgcgtggac acgacggtgc tggacttcgt cgcagacctg 60
 tccctggcct ccccgagacg ccctctctc tgcgacttcg caccgggggt ctccttgggg 120
 gaccagccc ttgcgctccg agaggggaaga cccaggagga tggcgcgggt tgaagagggg 180
 gaccagaag aagaggagtg cgaagtggac cagggggacg gagaagagga ggaggaagag 240
 gagcgcggaa gaggtgtctc cctattaggc cgccccaaaga ggaaaagggt gatcacctac 300
 gccagcgc ccaggcccaa catccgcgaa aggaagagga tgttcaacct caacgaggcc 360
 tttgaccagc tgcggaggaa ggtgcccacg tttgcttacg agaaaaggct gtcccggatc 420
 gagaccctcc gcctggccat cgtctacatc tccttcatga ccgagctctt ggagagctgt 480
 gagaagaagg aaagcggctg a 501

<210> 14
 <211> 166
 <212> PRT
 <213> Pan troglodytes

<400> 14
 Met Ala Ala Tyr Pro Glu Ser Cys Val Asp Thr Thr Val Leu Asp Phe
 1 5 10 15
 Val Ala Asp Leu Ser Leu Ala Ser Pro Arg Arg Pro Leu Leu Cys Asp
 20 25 30
 Phe Ala Pro Gly Val Ser Leu Gly Asp Pro Ala Leu Ala Leu Arg Glu
 35 40 45
 Gly Arg Pro Arg Arg Met Ala Arg Phe Glu Glu Gly Asp Pro Glu Glu
 50 55 60
 Glu Glu Cys Glu Val Asp Gln Gly Asp Gly Glu Glu Glu Glu Glu Glu
 65 70 75 80
 Glu Arg Gly Arg Gly Val Ser Leu Leu Gly Arg Pro Lys Arg Lys Arg
 85 90 95

48i

Val Ile Thr Tyr Ala Gln Arg Gln Ala Ala Asn Ile Arg Glu Arg Lys
 100 105 110

Arg Met Phe Asn Leu Asn Glu Ala Phe Asp Gln Leu Arg Arg Lys Val
 115 120 125

Pro Thr Phe Ala Tyr Glu Lys Arg Leu Ser Arg Ile Glu Thr Leu Arg
 130 135 140

Leu Ala Ile Val Tyr Ile Ser Phe Met Thr Glu Leu Leu Glu Ser Cys
 145 150 155 160

Glu Lys Lys Glu Ser Gly
 165

<210> 15
 <211> 372
 <212> DNA
 <213> Canis familiaris

<400> 15
 atggcgccct acccggaggg ctgcgtggac gccaccgtgc tggacttcgt cgccggacctg 60
 tccctggact cccccgggca cccgctcttc tgcgacttcg caccggggct tccctttggg 120
 gaccgggacc ttgtgctccg agaggggaagg cgcagaaggc tggcaggctt tgaggagcgc 180
 caggcggcca acatccgcga gaggaagcgg atgttcaacc tcaacgaggc cttcgaccag 240
 ctgcgacgga aggtgcccac ctttgcttac gagaagaggc tgtcccggat cgagacccta 300
 cgcttgcca tcgtctacat ttccttcatg accgagctcc tggagagctg cgcaaagaaa 360
 gaaaccggct ga 372

<210> 16
 <211> 123
 <212> PRT
 <213> Canis familiaris

<400> 16
 Met Ala Ala Tyr Pro Glu Gly Cys Val Asp Ala Thr Val Leu Asp Phe
 1 5 10 15
 Val Ala Asp Leu Ser Leu Asp Ser Pro Gly His Pro Leu Leu Cys Asp
 20 25 30
 Phe Ala Pro Gly Leu Pro Phe Gly Asp Arg Asp Leu Val Leu Arg Glu
 35 40 45
 Gly Arg Arg Arg Arg Leu Ala Gly Phe Glu Glu Arg Gln Ala Ala Asn
 50 55 60
 Ile Arg Glu Arg Lys Arg Met Phe Asn Leu Asn Glu Ala Phe Asp Gln
 65 70 75 80
 Leu Arg Arg Lys Val Pro Thr Phe Ala Tyr Glu Lys Arg Leu Ser Arg
 85 90 95

48j

Ile Glu Thr Leu Arg Leu Ala Ile Val Tyr Ile Ser Phe Met Thr Glu
 100 105 110

Leu Leu Glu Ser Cys Ala Lys Lys Glu Thr Gly
 115 120

<210> 17
 <211> 557
 <212> DNA
 <213> Bos taurus

<400> 17
 accaggcttg cccctccctt caataaatTT atgagacgca gggccaagca gacgcgatgg 60
 cagcctttcc cgagagctgc gtggacgcca ccgtcctgga cttcgtcgca gacctatccc 120
 tagcctcccc ggggcaccct ctctctgcg acttgacacc tagggTcccc tatgggaacc 180
 accaggacct tgtgctccga gacggaagac ccaggagtct ggcgcgTTTT gaggaagagg 240
 atccagaaga agaggagggg gaaggagaag agggggaaaa cgaggaggaa gaggagcacg 300
 ggagaggcgc ctccctactg ggccgcccc aaggaaaag agtgatcacc tacgcccagc 360
 gccaagcagc caacatccgc gagaggaagc ggatgttcaa cctcaacgag gccttcgatc 420
 agctgcggag gaaggtgccc actttcgctt acgagaagag gctctcccgg atcgagactc 480
 tacgcctggc cattgtctac atctccttca tgaccgagct cttggagagc ttggagaagg 540
 aaagagactg agccagg 557

<210> 18
 <211> 164
 <212> PRT
 <213> Bos taurus

<400> 18
 Met Ala Ala Phe Pro Glu Ser Cys Val Asp Ala Thr Val Leu Asp Phe
 1 5 10 15
 Val Ala Asp Leu Ser Leu Ala Ser Pro Gly His Pro Leu Leu Cys Asp
 20 25 30
 Leu Thr Pro Arg Val Pro Tyr Gly Asn His Gln Asp Leu Val Leu Arg
 35 40 45
 Asp Gly Arg Pro Arg Ser Leu Ala Arg Phe Glu Glu Glu Asp Pro Glu
 50 55 60
 Glu Glu Glu Gly Glu Gly Glu Glu Gly Glu Asn Glu Glu Glu Glu Glu
 65 70 75 80
 His Gly Arg Gly Ala Ser Leu Leu Gly Arg Pro Lys Arg Lys Arg Val
 85 90 95
 Ile Thr Tyr Ala Gln Arg Gln Ala Ala Asn Ile Arg Glu Arg Lys Arg
 100 105 110

48k

Met Phe Asn Leu Asn Glu Ala Phe Asp Gln Leu Arg Arg Lys Val Pro
 115 120 125

Thr Phe Ala Tyr Glu Lys Arg Leu Ser Arg Ile Glu Thr Leu Arg Leu
 130 135 140

Ala Ile Val Tyr Ile Ser Phe Met Thr Glu Leu Leu Glu Ser Leu Glu
 145 150 155 160

Lys Glu Arg Asp

<210> 19

<211> 552

<212> DNA

<213> Gallus gallus

<400> 19

atgtcagccg gcctcttccc ggcccaccgg cgcccggagc tgctccgcgg cacagctccg 60

ccgctcccct gcccgagcgg gctgctgggt gcctcgggtc tgggtttcgt ggccgacatc 120

tcgctgggag cccccagag ctcatctcgg gccggaccga gcctgggggtt aacctccgag 180

cctcccttcg gggacagaac cctgtcgtg cgggagggga tggcccgggg gttgcctttg 240

gctgccttcg gagacgggga tctcgaagac gaggaagaag aggaagaaga ggagagaatg 300

cggagcgctt cctactgga cagaccagg agaaagcggg ttatcaccta cgcccagcgc 360

caggcagcca acatccggga gaggaagagg atgttcaacc tcaacgaggc gttcgaccag 420

ctgaggaaga aggtgcccac cttcgcctac gagaagcggc tctcccggat agagaccttg 480

cgcttgcca tcgtgtacat ctcttcatg accgagctcc tgaacggctg cagcaggcag 540

gaggcgagct ag 552

<210> 20

<211> 183

<212> PRT

<213> Gallus gallus

<400> 20

Met Ser Ala Gly Leu Phe Pro Ala His Arg Arg Pro Glu Leu Leu Arg
 1 5 10 15

Gly Thr Ala Pro Pro Leu Pro Cys Pro Glu Arg Leu Leu Gly Ala Ser
 20 25 30

Val Leu Gly Phe Val Ala Asp Ile Ser Leu Gly Ala Pro Gln Ser Ser
 35 40 45

Ser Arg Ala Gly Pro Ser Leu Gly Leu Thr Ser Glu Pro Pro Phe Gly
 50 55 60

Asp Arg Thr Leu Ser Leu Arg Glu Gly Met Ala Arg Gly Leu Pro Leu
 65 70 75 80

481

Ala Ala Phe Gly Asp Gly Asp Leu Glu Asp Glu Glu Glu Glu Glu Glu
85 90 95

Glu Glu Arg Met Arg Ser Ala Ser Leu Leu Asp Arg Pro Arg Arg Lys
100 105 110

Arg Val Ile Thr Tyr Ala Gln Arg Gln Ala Ala Asn Ile Arg Glu Arg
115 120 125

Lys Arg Met Phe Asn Leu Asn Glu Ala Phe Asp Gln Leu Arg Lys Lys
130 135 140

Val Pro Thr Phe Ala Tyr Glu Lys Arg Leu Ser Arg Ile Glu Thr Leu
145 150 155 160

Arg Leu Ala Ile Val Tyr Ile Ser Phe Met Thr Glu Leu Leu Asn Gly
165 170 175

Cys Ser Arg Gln Glu Ala Ser
180

<210> 21
<211> 26
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 21
cagctccaca acctacatca ttccgt

26

<210> 22
<211> 12
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 22
acggaatgat gt

12

<210> 23
<211> 26
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 23
tagtctacca ctgctcgact gtaacg

26

<210> 24
<211> 26

48m

<212> DNA
<213> Artificial

<220>
<223> primer

<400> 24
cagagtgaac ccagtggaca tatctg

26

<210> 25
<211> 26
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 25
cagaatcctg tgctcacggt agttgc

26

<210> 26
<211> 26
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 26
actaaagtgg ctgcaagctg accagg

26

<210> 27
<211> 26
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 27
tggttcaggt gtggttccag aaccag

26

<210> 28
<211> 26
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 28
tctgaggttg ccaggaagca gtctcc

26

<210> 29
<211> 26

48n

<212> DNA
<213> Artificial

<220>
<223> primer

<400> 29
cctgggaaga ctgtcgcagt ttgatg

26

<210> 30
<211> 26
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 30
gaaggcctcg tttaggttga acatcc

26

<210> 31
<211> 26
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 31
atcggcagct atgccattcc tgcaag

26

<210> 32
<211> 26
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 32
tgctccaagc aagaagctct aactcc

26

<210> 33
<211> 26
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 33
gctgtcacgt cccaaggtt cattgg

26

<210> 34
<211> 26

480

<212> DNA
<213> Artificial

<220>
<223> primer

<400> 34
ggagcgcgatg cagtagtaag atgtgg 26

<210> 35
<211> 26
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 35
catatgatcg agcagaggaa gacacc 26

<210> 36
<211> 26
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 36
agtgcgaaca ccgtagtgct gacagg 26

<210> 37
<211> 26
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 37
gttcccaagg aaagtgtcag agttgg 26

<210> 38
<211> 26
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 38
gaagctggaa agcctccagg tgttcc 26

<210> 39
<211> 26

48p

<212> DNA
<213> Artificial

<220>
<223> primer

<400> 39
ctccgagcag acaccatgac cttagc 26

<210> 40
<211> 26
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 40
aggagtaggg cttgtctccc aacctg 26

<210> 41
<211> 26
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 41
cactcctgtg tctagctgcc agatgc 26

<210> 42
<211> 26
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 42
agtgcgaaca ccgtagtgct gacagg 26

<210> 43
<211> 26
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 43
tgagccgcag gtctgtggat ccatcc 26

<210> 44
<211> 26

48q

<212> DNA
<213> Artificial

<220>
<223> primer

<400> 44
tccctgttcc tggccttagt cctagg

26

<210> 45
<211> 26
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 45
atcctccgag tggacattca catagg

26

<210> 46
<211> 27
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 46
atgtccagca aatagagatc gctacac

27

64409-36

49

CLAIMS:

1. A polynucleotide probe or polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which hybridizes under stringent conditions with a polynucleotide consisting of a
5 nucleotide sequence of a Nato3 gene, or a complementary sequence thereto, wherein the stringent conditions comprise washing in 0.2xSSC, 0.1% SDS at 60°C to 65°C.
2. The polynucleotide probe or polynucleotide primer according to claim 1, which consists of a polynucleotide comprising a sequence of at least
10 10 contiguous nucleotides of a nucleotide sequence of the Nato3 gene, or a complementary sequence thereto.
3. The polynucleotide probe or polynucleotide primer according to claim 1 or 2, wherein the nucleotide sequence of the Nato3 gene is a nucleotide sequence comprising a part or all of a nucleotide sequence selected from the
15 group consisting of nucleotides 1-365 and 534-640 of SEQ ID NO:1, nucleotides 1-376 and 545-662 of SEQ ID NO:3, nucleotides 1-306 and 475-501 of SEQ ID NO:5, nucleotides 1-377 and 546-886 of SEQ ID NO:7, nucleotides 1-312 and 481-507 of SEQ ID NO:9, nucleotides 1-306 and 475-501 of SEQ ID NO:11, nucleotides 1-306 and 475-501 of SEQ ID NO:13,
20 nucleotides 1-177 and 346-372 of SEQ ID NO:15, nucleotides 1-359 and 528-557 of SEQ ID NO:17, nucleotides 1-357 and 523-552 of SEQ ID NO:19.
4. The polynucleotide probe or polynucleotide primer according to any one of claims 1 to 3, which is at least 15 bases in length.
5. A polynucleotide primer set comprising two or more kinds of the
25 polynucleotide primers according to any one of claims 1 to 4.
6. An antibody that binds specifically to a Nato3 protein, or a part thereof, for use in the detection or selection of a dopaminergic neuron

64409-36

50

proliferative progenitor cell.

7. The antibody according claim 6, wherein the Nato3 protein, or a part thereof is a protein comprising at least 6 amino acid residues or all of an amino acid sequence selected from the group consisting of amino acids 1-102 and
5 159-166 of SEQ ID NO:2, amino acids 1-102 and 159-166 of SEQ ID NO:4, amino acids 1-102 and 159-166 of SEQ ID NO:6, amino acids 1-104 and 161-168 of SEQ ID NO:8, amino acids 1-104 and 161-168 of SEQ ID NO:10, amino acids 1-102 and 159-166 of SEQ ID NO:12, amino acids 1-102 and 159-166 of SEQ ID NO:14, amino acids 1-59 and 116-123 of SEQ ID NO:16,
10 amino acids 1-101 and 158-164 of SEQ ID NO:18, amino acids 1-119 and 176-183 of SEQ ID NO:20.

8. A method for detecting or selecting a dopaminergic neuron proliferative progenitor cell, comprising the step of detecting expression of a Nato3 gene.

15 9. The method according to claim 8, wherein the step of detecting expression of the Nato3 gene comprises the steps of:

(a) contacting a polynucleotide derived from a cell sample to be tested, with the polynucleotide probe according to any one of claims 1 to 4; and

(b) detecting a hybridization complex,

20 wherein the cell sample to be tested is a cell obtained from a ventral region of an embryo midbrain, and wherein the cell is an ES cell induced to differentiate into a dopaminergic neuron proliferative progenitor cell.

10. The method according to claim 9, wherein in step (a), mRNA prepared from the cell sample to be tested or a complementary
25 DNA (cDNA) transcribed from the mRNA is contacted with the polynucleotide probe.

64409-36

51

11. The method according to claim 8, wherein the step of detecting expression of the Nato3 gene comprises the steps of:

(i) performing a nucleic acid amplification method by using a polynucleotide derived from a cell sample to be tested as a template and the polynucleotide primer according to any one of claims 1 to 4, or the polynucleotide primer set according to claim 5; and

(ii) detecting a formed amplification product;

wherein the cell sample to be tested is a cell obtained from a ventral region of an embryo midbrain, and wherein the cell is an ES cell induced to differentiate into a dopaminergic neuron proliferative progenitor cell.

12. The method according to claim 11, wherein in step (i), mRNA prepared from the cell sample to be tested or a complementary DNA (cDNA) transcribed from the mRNA is used as a template.

13. The method according to claim 8, wherein the step of detecting expression of the Nato3 gene comprises the steps of:

(i) contacting a protein derived from a cell sample to be tested, with the antibody according to claim 6 or 7; and

(ii) detecting an antigen-antibody complex;

wherein the cell sample to be tested is a cell obtained from a ventral region of an embryo midbrain, and wherein the cell is an ES cell induced to differentiate into a dopaminergic neuron proliferative progenitor cell.

14. The method according to any one of claims 9 to 13, wherein the differentiation induction is carried out by a stromal cell-derived inducing activity (SDIA) method.

.64409-36

52

15. A kit comprising at least the polynucleotide probe according to any one of claims 1 to 4 and instructions for using the probe to detect or select a dopaminergic neuron proliferative progenitor cell.

16. A kit comprising at least the polynucleotide primer according to any one of claims 1 to 4 or the polynucleotide primer set according to claim 5 and instructions for using the primer to detect or select a dopaminergic neuron proliferative progenitor cell.

17. A kit comprising at least the antibody according to claim 6 or 7 and instructions for using the antibody to detect or select a dopaminergic neuron proliferative progenitor cell.

18. A method for screening for an effective substance for inducing differentiation into a dopaminergic neuron proliferative progenitor cell, comprising the steps of:

(i) contacting a cell that can differentiate into a dopaminergic neuron proliferative progenitor cell, with a substance to be tested; and

(ii) detecting expression of a Nato3 gene in the cell contacted with the substance to be tested.

19. A method for producing a dopaminergic neuron proliferative progenitor cell, comprising the steps of:

(i) obtaining cells that can contain a dopaminergic neuron proliferative progenitor cell;

(ii) detecting or selecting the dopaminergic neuron proliferative progenitor cell, by using the method according to any one of claims 8 to 14; and

(iii) culturing the cell detected or selected in step (ii).

.64409-36

53

20. Use of a polynucleotide that hybridizes under stringent conditions with a polynucleotide consisting of a nucleotide sequence of a Nato3 gene, or a complementary sequence thereto, for the detection or selection of a dopaminergic neuron proliferative progenitor cell, wherein the stringent
5 conditions comprise washing in 0.2xSSC, 0.1% SDS at 60°C to 65°C.
21. The use according to claim 20, wherein the polynucleotide that hybridizes under stringent conditions consists of a sequence of at least 10 contiguous nucleotides of a nucleotide sequence of the Nato3 gene, or a complementary sequence thereto.
- 10 22. The use according to claim 20 or 21, wherein the nucleotide sequence of the Nato3 gene is a nucleotide sequence comprising a part or all of a nucleotide sequence selected from the group consisting of nucleotides 1-365 and 534-640 of SEQ ID NO:1, nucleotides 1-376 and 545-662 of SEQ ID NO:3, nucleotides 1-306 and 475-501 of SEQ ID NO:5,
15 nucleotides 1-377 and 546-886 of SEQ ID NO:7, nucleotides 1-312 and 481-507 of SEQ ID NO:9, nucleotides 1-306 and 475-501 of SEQ ID NO:11, nucleotides 1-306 and 475-501 of SEQ ID NO:13, nucleotides 1-177 and 346-372 of SEQ ID NO:15, nucleotides 1-359 and 528-557 of SEQ ID NO:17, nucleotides 1-357 and 523-552 of SEQ ID NO:19.
- 20 23. The use according to any one of claims 20 to 22, wherein the polynucleotide that hybridizes under stringent conditions is at least 15 bases in length.
24. Use of an antibody that binds specifically to a Nato3 protein, or a part thereof, for the detection or selection of a dopaminergic neuron proliferative
25 progenitor cell.
25. The use according to claim 24, wherein the Nato3 protein, or a part thereof is a protein comprising at least 6 amino acid residues or all of an amino acid sequence selected from the group consisting of amino acids

.64409-36

54

1-102 and 159-166 of SEQ ID NO:2, amino acids 1-102 and 159-166 of
SEQ ID NO:4, amino acids 1-102 and 159-166 of SEQ ID NO:6, amino acids
1-104 and 161-168 of SEQ ID NO:8, amino acids 1-104 and 161-168 of
SEQ ID NO:10, amino acids 1-102 and 159-166 of SEQ ID NO:12, amino acids
5 1-102 and 159-166 of SEQ ID NO:14, amino acids 1-59 and 116-123 of
SEQ ID NO:16, amino acids 1-101 and 158-164 of SEQ ID NO:18, amino acids
1-119 and 176-183 of SEQ ID NO:20.

Application number / numéro de demande

JPO6/316249

Figures:

1-8

Pages:

1-6

Unscannable item(s)

received with this application

To inquire if you can order a copy of the unscannable items, please visit the
CIPO WebSite at [HTTP://CIPO.GC.CA](http://CIPO.GC.CA).

Item(s) ne pouvant être balayés

Documents reçus avec cette demande ne pouvant être balayés.

Pour vous renseigner si vous pouvez commander une copie des items ne
pouvant être balayés, veuillez visiter le site web de l'OPIC au [HTTP://CIPO.GC.CA](http://CIPO.GC.CA)